Dysregulated miRNA (Reference)	Expression status	Proposed target gene

 miR-1 [53] let-7d [55] miR-17 and miR-20a [57] miR-29 [58-59] miR-34 [63] miR-99 family (miR-100 and miR-99a) [64] miR-125b [41] miR-126 [66] miR-133a [67] miR-138 [70-71] miR-153 [72] miR-200 [73] miR-200c [74] miR-222 [75] miR-363 [77] miR-375 [1] 	 Underexpression Underexpression Underexpression Underexpression Overexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression 	 TAGLN2Twist, Snail ITGβ8 LAMC2, ITGA6, TGF-β Unknown IGFIR, mTOR KLF13, CXCL1 and FOXA1 VEGF-A, bFGF MSN GNA12, RhoC and ROCK2 SNAI1 and ZEB2 ZEB1,ZEB2 BMI1/ZEB1 MMP-1 Podoplanin(PDPN) Unknown

Dysregulated miRNA (Reference)	Expression status	Proposed target gene

miR-1 [53] let-7d [55] miR-17 and miR-20a [57] miR-29 [58-59] miR-34 [63] miR-99 family (miR-100 and miR-99a) [64] miR-125b [41] miR-126 [66] miR-133a [67] miR-138 [70-71] miR-153	Underexpression Und	TAGLN2Twist, Snail ITGβ8 LAMC2, ITGA6, TGF-β Unknown IGFIR, mTOR KLF13, CXCL1 and FOXA1 VEG

[72] miR-200 [73] miR-200c [74] miR-222 [75] miR-363 [77] miR-375 [1]	erexpression Underexpression Underexpression Overexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression Underexpression	F-A, bFGF MSN GNA12, RhoC and ROCK2 SNAI1 and ZEB2 ZEB1,ZEB2 BMI1/ZEB1 MMP-1 Podoplanin(PDPN) Unknown


Internet Resource	URL

Sequence motif searches

Pfam	http://www.sanger.co.uk/Pfam/

PRINTS	http://www.biochem.ucl.ac.uk/bsm/dbbrowser/PRINTS/

Prosite	http://www.expasy.org/prosite/

SMART	http://smart.embl-heidelberg.de

Superfamily	http://supfam.mrc-lmb.cam.ac.uk/SUPERFAMILY/hmm.html

Structural comparison

CATH	http://www.cathdb.info/latest/index.html

DaliLite	http://www.ebi.ac.uk/DaliLite/

SCOP	http://scop.mrc-lmb.cam.ac.uk/scop/

SSM	http://www.ebi.ac.uk/msd-srv/ssm/

Alignment software

BLAST	http://www.ncbi.nlm.nih.gov/blast/Blast.cgi

ClustalW	http://www.ebi.ac.uk/Tools/clustalw2/

Dcode	http://www.dcode.org

MEGA	http://www.megasoftware.net/

Muscle	http://www.ebi.ac.uk/muscle/

T-coffee	http://www.tcoffee.org/

Alignment optimization

GBlocks	http://molevol.ibmb.csic.es/Gblocks.html

GeneDoc	http://www.nrbsc.org/gfx/genedoc/index.html

PHYLIP	http://evolution.genetics.washington.edu/phylip.html

Phylogenetic analysis software

MrBayes	http://mrbayes.csit.fsu.edu/

PhyML	http://atgc.lirmm.fr/phyml/

PHYLIP	http://evolution.genetics.washington.edu/phylip.html

Tree-Puzzle	http://www.tree-puzzle.de/

MEGA	http://www.megasoftware.net/

Visualization

Pymol (structural)	http://pymol.sourceforge.net/

NJplot (phylogeny)	http://pbil.univ-lyon1.fr/software/njplot.html

MEGA	http://www.megasoftware.net/

Swiss-Model (structural)	http://swissmodel.expasy.org/

TreeView (phylogeny)	http://taxonomy.zoology.gla.ac.uk/rod/treeview.html

Databases

Ensembl (Sanger project)	http://www.ensembl.org

PDB	http://www.rcsb.org/pdb/home/home.do

NCBI	http://www.ncbi.nlm.nih.gov/sites/gquery?itool=toolbar

Superfamily	http://supfam.mrc-lmb.cam.ac.uk/SUPERFAMILY/hmm.html

UniProt	http://www.expasy.uniprot.org/

Internet Resource	URL

Sequence motif searches

Pfam	http://www.sanger.co.uk/Pfam/

PRINTS	http://www.biochem.ucl.ac.uk/bsm/dbbrowser/PRINTS/

Prosite	http://www.expasy.org/prosite/

SMART	http://smart.embl-heidelberg.de

Superfamily	http://supfam.mrc-lmb.cam.ac.uk/SUPERFAMILY/hmm.html

Structural comparison

CATH	http://www.cathdb.info/latest/index.html

DaliLite	http://www.ebi.ac.uk/DaliLite/

S	http://scop.mrc-lmb.c

Internet Resource	URL

COP	am.ac.uk/scop/

SSM	http://www.ebi.ac.uk/msd-srv/ssm/

Alignment software

BLAST	http://www.ncbi.nlm.nih.gov/blast/Blast.cgi

ClustalW	http://www.ebi.ac.uk/Tools/clustalw2/

Dcode	http://www.dcode.org

MEGA	http://www.megasoftware.net/

Muscle	http://www.ebi.ac.uk/muscle/

T-coffee	http://www.tcoffee.org/

Alignment optimization

GBlocks	http://molevol.ibmb.csic.es/Gblocks.html

GeneDoc	http://www.nrbsc.org/gfx/genedoc/index.html

PHYLIP	http://evolution.genetics.washington.edu/phylip.html

Phylogenetic analysis software

MrBayes	http://mrbayes.csit.fsu.edu/

PhyML	http://atgc.lirmm.fr/phyml/

PHYLIP	http://evolution.genetics.washington.edu/phylip.html

Tree-Puzzle	http://www.tree-puzzle.de/

MEGA	http://www.megasoftware.net/

Visualization

Pymol (structural)	http://pymol.sourceforge.net/

NJplot (phylogeny)	http://pbil.univ-lyon1.fr/software/njplot.html

MEGA	http://www.megasoftware.net/

Swiss-Model (structural)	http://swissmodel.expasy.org/

TreeView (phylogeny)	http://taxonomy.zoology.gla.ac.uk/rod/treeview.html

Databases

Ensembl (Sanger project)	http://www.ensembl.org

PDB	http://www.rcsb.org/pdb/home/home.do

NCBI	http://www.ncbi.nlm.nih.gov/sites/gquery?itool=toolbar

Superfamily	http://supfam.mrc-lmb.cam.ac.uk/SUPERFAMILY/hmm.html

UniProt	http://www.expasy.uniprot.org/


Parameter	Pediatric Journals(n = 42)	General Journals(n = 68)

Risk of Bias†

 Adequate Sequence Generation	29 (69)	53 (78)

 Adequate Concealment of Allocation	23 (55)	50 (74)

 Adequate Blinding of Participants and Providers	21 (50)	34 (50)

 Adequate Blinding of Outcome Assessment	25 (60)	53 (78)

 Adequate Handling of Missing Data	30 (72)	53 (78)

Parameter	Pediatric Journals(n = 42)

Risk of Bias†

Adequate Sequence Generation	29 (69)

Adequate Concealment of Allocation	23 (55)

Adequate Blinding of Participants and Providers	21 (50)

Adequate Blinding of Outcome Assessment	25 (60)

Adequate Handling of Missing Data	30 (72)


 	Stable plaque (SP) 	Unstable plaque (UP) 	P value

 	Median 	25–75% CI	Median 	25–75% CI

Fibrous cap (in μm)	267	181–440	96	0–223	0.02

LCR	0.21	0.08–0.28	0.64	0.54–0.76	<0.001

Neovessels (/0.2 mm2)	0	0–0.3	3	3–5	<0.001


Antipsychotics	MAOIs	Anticonvulsants/Anxiolytics/Others

Chlorpromazine	Hydroxylamine	Benztropine	Phenylephrine

Haloperidol	Selegiline	Phenytoin	Phenobarbital

Sulpiride	Pargyline	Diazepam	Chlordiazepoxide

Flupenthixol	Quinacrine	Nitrazepam


	I.D. 34	I.D. 56	I.D. 81

Tube voltage [kV]	220	220	160

Tube current [μA]	180	180	160

Power [W]	39.6	39.6	25.6

Exposure time [ms]	499	499	999

Filter	Cu 1 mm	Cu 1 mm	none

Number of projections	1200	1200	1200

Voxel size [μm]	28	34	49.5

FOV in horizontal plane [mm]	33	58	82

FOV vertical [mm]	74	104	75

Measurement time [min]	40	60	20*


 	<underline>Outcome: high activity/behavior in children for corresponding activity/behavior category</underline>

Maternal exposure	Baseline	Follow-up

Commuting

 Low activity	1.00	1.00

 High activity	2.72 (1.08, 6.87)‡	3.13 (1.37, 7.16)†

Leisure-time sports

 Low activity	1.00	1.00

 High activity	3.61 (1.14, 11.41)‡	0.87 (0.26, 2.93)

Sedentary

 Low sedentarybehavior	*	1.00

 High sedentarybehavior	*	0.58 (0.35, 0.97)‡

	Outcome: high activity/behavior in children for corresponding activity/behavior category

Maternal exposure	Baseline	Follow-up

Commuting

L	1	1.0

	Outcome: high activity/behavior in children for corresponding activity/behavior category

Maternal exposure	Baseline	Follow-up

ow activity	.00	0

High activity	2.72 (1.08, 6.87)‡	3.13 (1.37, 7.16)†

Leisure-time sports

Low activity	1.00	1.00

High activity	3.61 (1.14, 11.41)‡	0.87 (0.26, 2.93)

Sedentary

Low sedentarybehavior	*	1.00

High sedentarybehavior	*	0.58 (0.35, 0.97)‡


Error size	Mean	SD	95% CI

Large error	10.48	4.68	[8.28, 12.67]


	IFT-A	IFT-B

	IFT122	IFT140	IFT172	IFT52	IFT80	IFT88	TTC-26	TTC30a

Attheya septentrionalis				+

Aulacoseira subarctica	+			+	+	+	+	+

Chaetoceros curvisetus				+		+	+

Corethron hystrix				+

Corethron pennatum				+		+

Coscinodiscus wailesii			+	+	+	+	+	+

Cyclotella meneghiniana				+		+	+	+

Dactyliosolen fragilissimus				+	+

Ditylum brightwellii	+		+	+	+	+	+	+

Extubocellulus spinifer			+	+		+		+

Leptocylindrus aporus				+	+		+

Leptocylindrus danicus	+	+	+	+	+	+	+	+

Leptocylindrus hargravesii	+	+	+	+	+	+	+

Minutocellus polymorphus				+	+	+		+

Odontella aurita	+		+	+	+	+	+	+

Proboscia alata	+	+	+	+	+	+	+	+

Proboscia inermis					+	+	+

Rhizosolenia setigera	+	+	+	+		+

Skeletonema marinoi				+		+		+

Skeletonema menzelii				+				+

Stephanopyxis turris	+		+	+	+	+	+	+

Thalassiosira pseudonanaa				+		+		+

Thalassiosira rotula				+		+		+

Thalassiosira weissflogii	+	+	+	+	+	+	+	+


Cell type	Environment	Number of animals	Peripheral	Intermediate	Central

% EdU + a	% EdU + a	% EdU + a

Number of cells	Number of cells	Number of cells

Vsx2orJ	orJ	4	4% ± 2%	20% ± 3%	31% ± 2%

1,880 cells	2,554 cells	2,490 cells

Vsx2orJ	Mutant chimera	5	26% ± 8%	21% ± 4%	21% ± 5%

			732 cells	798 cells	519 cells

Vsx2wt	Wild type	3	40% ± 5%	47% ± 4%	32% ± 3%

1,390 cells	2,207 cells	2,186 cells

Vsx2wt	Control chimera	4	46% ± 5%	42% ± 5%	28% ± 1%

594 cells	1,093 cells	883 cells

Yfp+	Mutant chimera	3	43% ± 8%	43% ± 8%	32% ± 5%

1,209 cells	2,608 cells	2,169 cells

Yfp+	Control chimera	4	47% ± 2%	44% ± 3%	38% ± 1%

809 cells	1,048 cells	1,378 cells

Cell type	Environment	Number of animals	Peripheral

% EdU + a

Number of cells

Vsx2orJ	orJ	4	4% ± 2%

1,880 cells

Vsx2orJ	Mutant chimera	5	26% ± 8%

			732 cells

Vsx2wt	Wild type	3	40% ± 5%

1,390 cells

Vsx2wt	Control chimera	4	46% ± 5%

594 cells

Yfp+	Mutant chimera	3	43% ± 8%

1,209 cells

Yfp+	Control chimera	4	47% ± 2%

809 cells

Intermediate	Central

% EdU + a	% EdU + a

Number of cells	Number of cells

20% ± 3%	31% ± 2%

2,554 cells	2,490 cells

21% ± 4%	21% ± 5%

798 cells	519 cells

47% ± 4%	32% ± 3%

2,207 cells	2,186 cells

42% ± 5%	28% ± 1%

1,093 cells	883 cells

43% ± 8%	32% ± 5%

2,608 cells	2,169 cells

44% ± 3%	38% ± 1%

1,048 cells	1,378 cells


Farmer	78.2	1.83	[0.7–5]	0.0009	86.0	2.01	[0.6–6.6]	0.1167

Other	7.7	0.13	[0.04–0.4]	24.3	0.54	[0.2–1.2]

Main material of roof	0.738		NS

Leaves	36.4	1.00

Aluminium (tole)	50.3	1.09	[0.7–2]

Education		0.95	[0.8–1.1]	0.477		NS

Household		1.04	[1.0–1.1]	0.045		NS

House structure	NS						0.01

On ground				82.4	1.00

On stilts				48.1	0.24	[0.1–0.7]

Nr of buffaloes owned		NS				0.63	[0.4–0.9]	0.021

Total number of bednets in the household		NS				0.72	[0.5–1.0]	0.051

Total number of nights spent in the field		NA				1.00	[1.0–1.0]	0.854

Working in the forest during the study		NA				0.55	[0.2–1.5]	0.255

Total number of nights spent in the forest		NA				1.93	[0.6–6.5]	0.286

Having slept in another cluster during the study		NA				0.98	[0.3–3.1]	0.973


Patient		Mild (n e %)	Moderate (n e %)	Severe (n e %)

Caregiver	Use of medication prescribed by doctor	33 (36%)	29 (31%)	13 (14%)


Description	Example selected for inclusion

Promises (of reduced pain)	If I’m thinner/lose more weight then rejection and criticism won’t hurt so much.

Consolation	I may not be doing so well in some areas of my life but at least I’m thin.

Self-congratulations (on eating behaviour etc.)	I’m doing really well in controlling my eating today.

Threats	If I don’t keep my eating under control, I’m going to get obese and be rejected by everyone.

Cautions regarding eating	That food/eating situation is dangerous. I’m going to have to be really careful about what I eat.

Need to purge	I’m worried that I’ve eaten too much. I need to get rid of it by purging.

Need to exercise	I can’t afford to just sit around, I have to exercise more.

Self-disappointment (at ability to meet dietary ideals)	I’m so disappointed at myself: I’ve failed to live up to my dietary ideals again.

Self-abuse	I am so pathetic and useless. I have no discipline or self-control.

Self-punishment	Because I have failed to live up to my dietary ideals I deserve to be punished by denying myself food or exercising harder.

Self-criticism (lack of self-worth)	I’m such a failure. I try really hard to do well and make friends but I’m just not the type of person I want to be.

Comparisons (with others)	Look at her she’s so thin and she does it so easily. Why can’t I be like her?

Reinterpretations	When they say things like “you’re looking well”, what they’re really meaning is how much weight I’ve put on.

Sensory misperceptions	Just feel that stomach/Look at those thighs (etc.). I feel/look so fat/terrible.

Denial (of symptoms)	Feeling tired and/or cold doesn’t mean there’s anything wrong with me. I just have to be stronger.

Moral judgements	Practising self-restraint is an important virtue. I despise people who have no self-control.

Ruination of life	My concern about food and weight is threatening the other things I want to achieve/get out of life.

Weariness (of constantly thinking about food)	I’m so fed up of constantly thinking about food and what I eat.

Misery (of living with an ED)	Life is so miserable/lonely living like this.

Lost identity	I feel like I don’t really know who I am/what I stand for any more. I’ve lost touch with the real me.

Need for secrecy	People mustn’t find out the way I think or behave concerning food.

Rebellion	I’m fed up of trying to control what I eat. I’m just going to eat whatever and as much as I want!

Pride in ED	When I think about how self-controlled I am around food compared to the average person, I feel quite proud of what I can achieve.

Fear of life without ED	If I let go of my strict control and ideals around eating, I’m really quite frightened about what life would be like.

Description	Example selected for inclusion

Promises (of reduced pain)	If I’m thinner/lose more weight then rejection and criticism won’t hurt so much.

Consolation	I may not be doing so well in some areas of my life but at least I’m thin.

Self-congratulations (on eating behaviour etc.)	I’m doing really well in controlling my eating today.

Threats	If I don’t keep my eating under control, I’m going to get obese and be rejected by everyone.

Cautions regarding eating	That food/eating situation is dangerous. I’m going to have to be really careful about what I eat.

Need to purge	I’m worried that I’ve eaten too much. I need to get rid of it by purging.

Need to exercise	I can’t afford to just sit around, I have to exercise more.

Self-disappointment (at ab	I’m so disappointed at m

ility to meet dietary ideals)	yself: I’ve failed to live up to my dietary ideals again.

Self-abuse	I am so pathetic and useless. I have no discipline or self-control.

Self-punishment	Because I have failed to live up to my dietary ideals I deserve to be punished by denying myself food or exercising harder.

Self-criticism (lack of self-worth)	I’m such a failure. I try really hard to do well and make friends but I’m just not the type of person I want to be.

Comparisons (with others)	Look at her she’s so thin and she does it so easily. Why can’t I be like her?

Reinterpretations	When they say things like “you’re looking well”, what they’re really meaning is how much weight I’ve put on.

Sensory misperceptions	Just feel that stomach/Look at those thighs (etc.). I feel/look so fat/terrible.

Denial (of symptoms)	Feeling tired and/or cold doesn’t mean there’s anything wrong with me. I just have to be stronger.

Moral judgements	Practising self-restraint is an important virtue. I despise people who have no self-control.

Ruination of life	My concern about food and weight is threatening the other things I want to achieve/get out of life.

Weariness (of constantly thinking about food)	I’m so fed up of constantly thinking about food and what I eat.

Misery (of living with an ED)	Life is so miserable/lonely living like this.

Lost identity	I feel like I don’t really know who I am/what I stand for any more. I’ve lost touch with the real me.

Need for secrecy	People mustn’t find out the way I think or behave concerning food.

Rebellion	I’m fed up of trying to control what I eat. I’m just going to eat whatever and as much as I want!

Pride in ED	When I think about how self-controlled I am around food compared to the average person, I feel quite proud of what I can achieve.

Fear of life without ED	If I let go of my strict control and ideals around eating, I’m really quite frightened about what life would be like.


	Random sample	Symptom sample	Total

Rhinitis (%)	303 (42.8)	288 (67.5)	591 (52.1)


	Focus groups	Systematic review	Online user-generated content

METHODS

Main approach	Eight focus groups (n = 74)	Searching of databases from the earliest date to October 2014	Analysis of 3,373 reader comments posted online in response to a news article on incentives

	Inclusion criteria: UK adults, aged 18+ years	Databases searched: Medline; Embase; Web of Knowledge; CINAHL; PsycINFO; ASSIA; Sociological Abstracts; Scopus; The Philosopher’s Index; Cochrane Library; SSCI; IBSS	News article topic: feasibility study of financial incentives for breastfeeding

	Method: face-to-face focus groups; audio-recorded; lasting on average 60 min	Inclusion criteria: English language title Published in a peer-reviewed journal Explored acceptability of financial incentives for healthy behaviors Acceptability explored in the public, policy makers, potential recipients, and practitioners	Online news sites searched: BBC; Guardian; Daily Mail; Telegraph; Independent; The Sun

	Analytical approach: thematic analysis using NVivo 10	Analytical approach: thematic analysis using NVivo 10	Inclusion criteria: popular websites defined as those that achieved an average monthly audience of at least five million unique viewers per month across laptop computers, desktop computers, and mobile devices in April and May 2013 Analytical approach: thematic analysis using NVivo 10

RESULTS

Main themes	The nature of fair exchange	Fair exchange	Children are a lifestyle choice

	Design and delivery of incentive schemes	Design and delivery	Financial incentives for breastfeeding are discriminatory and divisive

	Effectiveness and cost-effectiveness	Effectiveness and cost-effectiveness	Creating a culture of entitlement

	Recipients	Recipients	Financial incentives for breastfeeding are potentially insulting

	Impact on individuals and wider society	Impact on individuals and wider society	Psychological impacts on recipients

	“Other” issues		Effectiveness and cost-effectiveness

			Generating initial motivation

			Design and delivery

			Informed choice


Interaction	Odds ratio	Lower 95% CI	Upper 95% CI

Model GP

 age ≥60

low SES to high	1.84	1.54	2.20

middle SES to high	1.57	1.32	1.87

 age<60

low SES to high	0.99	0.89	1.09

middle SES to high	0.96	0.86	1.06

 age ≥60 vs age<60

low SES	4.46	3.93	5.05

middle SES	3.91	3.45	4.44

high SES	2.39	2.04	2.80

Model SD

 age ≥60

low SES to high	1.05	0.83	1.33

middle SES to high	1.08	0.86	1.35

 age<60

low SES to high	0.48	0.41	0.56

middle SES to high	0.78	0.68	0.90

 age ≥60 to age<60

low SES	4.66	3.85	5.65

middle SES	2.93	2.47	3.49

high SES	2.13	1.75	2.60

Interaction	Odds ratio	Lower 95% CI	Upper 95% CI

Model GP

age ≥60

low SES to high	1.84	1.54	2.20

middle SES to high	1.57	1.32	1.87

age<60

low SES to high			1

Interaction	Odds ratio	Lower 95% CI	Upper 95% CI

	0.99	0.89	.09

middle SES to high	0.96	0.86	1.06

age ≥60 vs age<60

low SES	4.46	3.93	5.05

middle SES	3.91	3.45	4.44

high SES	2.39	2.04	2.80

Model SD

age ≥60

low SES to high	1.05	0.83	1.33

middle SES to high	1.08	0.86	1.35

age<60

low SES to high	0.48	0.41	0.56

middle SES to high	0.78	0.68	0.90

age ≥60 to age<60

low SES	4.66	3.85	5.65

middle SES	2.93	2.47	3.49

high SES	2.13	1.75	2.60


Ebolavirus	IgM+	IgG+

al Combined	(46%)	2/40 (30%)


	All proteins	Human proteins

Total proteins	550,299	20,186

PTM proteins	112,985	13,080

PPI annotation (string)	326,227	17,833

PTM & PPI proteins	65,907	12,541

Drug-binding proteins(DrugBank)	–	1980

PTM & drug-binding proteins	–	1404


	xthr	xtbs	xthr and xtbs

Number of sequences reads obtained	30272	27602	57874

Number of clone sequences obtained	16548	14901	31449

Number of valid sequences	26440	22345	48785

Number of clones with valid sequences	15540	12266	27806

Number of clones with 5' and 3' EST	9354	11486	20840

Number of clones with 5' EST only	4831	0	4831

Number of clones with 3' EST only	1355	780	2135

Average trimmed EST length	522	546	534

Number of contigs	4327	4002	8756

Number of contigs groups	497	289	842

Number of contigs grouped	1210	649	2209

Number of unique contigs	3117	3353	6547

Nulmber of clones in contigs	9616	9268	15642

Number of singletons	7958	4262	17018

Number of clones in singletons	5924	2998	12164

Number of putative transcripts	9538	6640	19553

Max. assembled sequence length	3028	3144	3028

Average assembled sequence length	732	782	745

Max. assembled sequence size	147	144	159

Average assembled sequence size	6	5	5

Number of contigs containing

1	509	97	1152

2	1779	2155	3730

3	452	362	905

4–5	587	545	1159

6–10	505	476	952

11–20	283	207	479

21–30	91	90	174

31–50	80	41	118

50–100	31	26	76

>100	10	3	11

	xthr

Number of sequences reads obtained	30272

Number of clone sequences obtained	16548

Number of valid sequences	26440

Number of clones with valid sequences	15540

Number of clones with 5' and 3' EST	9354

Number of clones with 5' EST only	4831

Number of clones with 3' EST only	1355

Average trimmed EST length	522

Number of contigs	4327

Number of contigs groups	497

Number of contigs grouped	1210

Number of unique contigs	3117

Nulmber of clones in contigs	9616

Number of singletons	7958

Number of clones in singletons	5924

Number of putative transcripts	9538

Max. assembled sequence length	3028

Average assembled sequence length	732

Max. assembled sequence size	147

Average assembled sequence size	6

Number of contigs containing

1	509

2	1779

3	452

4–5	587

6–10	505

11–20	283

21–30	91

31–50	80

50–100	31

>100	10


 	N of articles

Exclusively women	15

Pregnant	8

Reproductive age/infertility evaluation	3

Postpartum	2

Others	2

Patients (men and women)	10

Inpatients	4

Primary care	3

Others	3

College students (men and women)	10

General population (men and women, online)	1

Total	36

	N of articles

General population (men and women, online)	1

Total	36


Age group (years)	Total	RVID (cm)	PADP (mm Hg)	TRVel (m/s)	PASP (mm Hg)	TVIRVOT (cm)	PVCSA (cm2)	PBF (L/min)	PVRECHO (Woods unit)

Total	15	2.8	10.2	2.16	19.1	20.7	3.52	5.22	1.22


Against	For

Mutilates healthy organCauses psychological distressInflicts a woundDestroys ability to be fruitfulViolates prohibition against castration	Prolongs life

nst	or

Mutilates healthy organCauses psychological distressInflicts a woundDestroys ability to be fruitfulViolates prohibition against castration	Prolongs life


	Consistent** increased brain activation across ROI’s after treatment (n = 6)	Consistent** decrease (or unchanged) brain activation across ROIs after treatment (n = 7)	Mixed neuroplastic pattern across ROIs after treatment (n = 10)	p value*

AMAT at baseline (s), mean (SD)	1691.6(479)	1070.5(753)	2041.7(349)	0.04

AMAT improvement (s), mean (SD)	693.3(471)	169.8 (203)	430(309)	0.02

Age in years, mean(SD)	58.17(6.8)	57.57 (13.6)	51.7(14.6)	ns

Time since stroke, in years, mean(SD)	2.28(1.5)	1.99 (1.3)	1.34(0.4)	ns

	Consistent** increased brain activation across ROI’s after treatment (n = 6)	Consistent** decrease (or unchanged) brain activation across ROIs after treatment (n = 7)	Mixed neuroplastic pattern across ROIs after treatment (n = 10)	p value*

AMAT improvement (s), mean (SD)	693.3(471)	169.8 (203)	430(309)	0.02

Age in years, mean(SD)	58.17(6.8)	57.57 (13.6)	51.7(14.6)	ns

Time since stroke, in years, mean(SD)	2.28(1.5)	1.99 (1.3)	1.34(0.4)	ns


	Patients who underwent a given number of invasive diagnostic procedures (%)

	RIC (N = 195)	Non-RIC (N = 132)

Total number of invasive diagnostic procedures performed

0a	9 (5)	10 (8)

1	99 (51)	68 (51)

2	67 (34)	41 (31)

≥3	20 (10)	13 (9)


		Spontaneous deliveriesa	Provider-initiated deliveries	All deliveries

	Gestation lengthb	Late preterm	Early term	Full term (reference)	Late preterm	Early term	Full term (reference)	Late preterm	Early term	Full term (reference)

	N	1812	9701	56 527	1 007	4535	7824	2819	14054	64351

Unadjusted analyses		OR (95% CI)c	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)

Anxiety groupsd	Very high	1.5 (1.1-2.0)	1.3 (1.2-1.5)	-	1.7 (1.2-2.3)	1.3 (1.0-1.6)	-	1.8 (1.4-2.2)	1.4 (1.3-1.6)	-


Author	Country (ethnicity)	Cases/controls	Diagnosis of cases	Selection of controls

Selvaraj	India (Asian)	210/120	Smear, culture, radiological, clinical response confirmed PTB	Normal healthy spouses and Tuberculosis Research Centre staff, ethnicity and area of residence matched

Fitness	Malawi (African)	181/533	Smear, culture, histology confirmed TB, HIV negative	No history or symptom of TB; not first or second degree relatives of the cases; age, sex and area of residence matched

Vejbaesya	Thailand (Asian)	149/147	Smear, culture, clinical and radiological response confirmed PTB, HIV negative	Unrelated healthy blood bank donors

Ates	Turkey (Caucasian)	128/80	Smear, culture, pathological, radiological , clinical response confirmed PTB,EPTB	No history of TB noted on chest radiography, age and sex matched

Trajkov	Republic of Macedonia (Caucasian)	75/301	Smear/culture confirmed PTB	No family history of TB, nationality and area of residence matched

Merza	Iran (Asian)	117/60	Smear and radiological confirmed PTB	Nurses, doctors and TB staff with no laboratory or clinical sign of diseases development, age, sex and nationality matched

Sharma	India (Asian)	185/155	Smear, culture, histology, radiological , clinical response confirmed PTB,EPTB,HIV negative without chronic illness	Without a family history of TB or any other related disease and a possibility of a latent tuberculosis infection, socioeconomic status and ethnicity matched

Anoosheh	Iran (Asian)	93/103	Smear and culture confirmed PTB	No history of TB

Lin	China (Asian)	46/40	Pathological examination and clinical response confirmed EPTB	NR


Molecular species	4 months	10 months	15 months

Fold Changes 1	p-value 2	Fold Changes 1	p-value 2	Fold Changes 1	p-value 2

Metabolites derived from arachidonic acid

Prostaglandin D2	0.99	0.941	0.46	< 0.001***	0.63	0.059


	Matchsticks (%)	Nine-dot (%)	Eight-coin (%)

s_inc+


Socio–demographic characteristic	N	Per cent (95 % CI)

Age group –

 11–15 years	53	3.3 (2.4–4.2)

 16–17 years	74	5.5 (4.3–6.7)

Highest level of parent/carer education –

 Bachelor degree or higher	54	4.7 (3.4–6.0)

 Diploma or cert III/IV	44	3.0 (2.1–4.0)

 Year 11 or 12	13	3.4 (1.5–5.3)

 Year 10 or below	16	5.7 (2.7–8.6)

Parent/carer labour force status –

 Both carers employed	59	3.4 (2.5–4.3)

 One carer employed, one carer not in employment	29	4.8 (2.8–6.8)

 Both carers not in employment	7	8.7 (2.3–15.0)

 Sole carer employed	24	3.9 (2.3–5.5)

 Sole carer not in employment	8	3.5 (0.9–6.1)

 Not stated	0	–

Housing tenure –

 Owned outright	12	2.5 (1.0–4.1)

 Owned with a mortgage	65	3.5 (2.6–4.4)

 Rented – public housing	9	6.5 (2.4–10.6)

 Rented – other	41	5.3 (3.5–7.1)

 Other	0	–

Annual household income –

 Less than $52,000	32	4.4 (2.8–6.0)

 $52,000–129,000	54	3.6 (2.6–4.6)

 $130,000 or more	37	4.3 (2.9–5.8)

Child’s country of birth –

 Australia	107	3.7 (3.0–4.5)

 Overseas	20	5.0 (2.6–7.4)

Family type –

 Intact family	73	3.8 (2.9–4.7)

 Step family	7	3.7 (0.7–6.7)

 Blended familya	11	4.4 (1.6–7.1)

 Lone parent family	33	3.9 (2.5–5.3)

 Other family	3	8.8 (0.00–18.8)

Geographic level of remoteness –

 Major cities	97	4.6 (3.6–5.5)

 Inner regional Australia	22	2.8 (1.6–4.0)

 Outer regional Australia	6	2.6 (0.2–5.0)

 Remote Australia	2	3.7 (0.0–8.8)

Socio–demographic characteristic

Age group –

11–15 years

16–17 years

Highest level of parent/carer education –

Bachelor degree or higher

Diploma or cert III/IV

Year 11 or 12

Year 10 or below

Parent/carer labour force status –

Both carers employed

One carer employed, one carer not in employment

Both carers not in employment

Sole carer employed

Sole carer not in employment

Not stated

Housing tenure –

Owned outright

Owned with a mortgage

Rented – public housing

Rented – other

Other

Annual household income –

Less than $52,000

$52,000–129,000

$130,000 or more

Child’s country of birth –

Australia

Overseas

Family type –

Intact family

Step family

Blended familya

Lone parent family

Other family

Geographic level of remoteness –

Major cities

Inner regional Australia

Outer regional Australia

Remote Australia


Feature	Description	Information gain

Feature 1	Number of neighbours in which the label is assigned	0.16

Feature 2	Sum of similarity scores between the document and all the neighbours’ document where the label appears	0.17

Feature 3	Check whether all constituted tokens of the label appear in the target document	0.01

Feature 4	Check whether one of the label entries appears in the target document	0.03

Feature 5	Frequency of the label if it is contained in the document	0.03

Feature 6	Check if the label is contained in the document title	0.02

Feature

Feature 1

Feature 2

Feature 3

Feature 4

Feature 5

Feature 6

Description	Information gain

Number of neighbours in which the label is assigned	0.16

Sum of similarity scores between the document and all the neighbours’ document where the label appears	0.17

Check whether all constituted tokens of the label appear in the target document	0.01

Check whether one of the label entries appears in the target document	0.03

Frequency of the label if it is contained in the document	0.03

Check if the label is contained in the document title	0.02


			Larval temperature (°C)

	Adult temperature (°C)		27 ± 1 (with respect to 23 °C)	31 ± 1 (with respect to 23 °C)	31 ± 1 (with respect to 27 °C)

1st blood meal		Log odds of laying eggs	−0.783b	−1.658	−0.876

23 ± 1	log-likelihood ratio test	−1.187	−2.455	−1.515

p-value	0.235	0.014	0.130

27 ± 1	Log odds of laying eggs	−2.565	−4.069	−1.504

log-likelihood ratio test	−2.383	−3.828	−3.086

p-value	0.017	<0.001	0.002

31 ± 1	Log odds of laying eggs	0.767c	−0.028	−0.795

	log-likelihood ratio test	1.386	−0.048	−1.392

	p-value	0.166	0.962	0.164

2nd blood meal		Log odds of laying eggs	−1.952	−3.312	−1.36

23 ± 1	log-likelihood ratio test	−2.398	−3.805	−2.276

p-value	0.016	<0.001	0.023

27 ± 1	Log odds of laying eggs	−1.161	−2.496	−1.335

log-likelihood ratio test	−1.613	−3.486	−2.534

p-value	0.107	<0.001	0.011

31 ± 1	Log odds of laying eggs	1.121	0.359	−0.762

log-likelihood ratio test	1.557	0.465	−1.218

p-value	0.120	0.642	0.223

	Adult temperature (°C)

1st blood meal

23 ± 1

27 ± 1

31 ± 1

2nd blood meal

23 ± 1

27 ± 1

31 ± 1

	Larval temperature (°C)

	27 ± 1 (with respect to 23 °C)	31 ± 1 (with respect to 23 °C)	31 ± 1 (with respect to 27 °C)

Log odds of laying eggs	−0.783b	−1.658	−0.876

log-likelihood ratio test	−1.187	−2.455	−1.515

p-value	0.235	0.014	0.130

Log odds of laying eggs	−2.565	−4.069	−1.504

log-likelihood ratio test	−2.383	−3.828	−3.086

p-value	0.017	<0.001	0.002

Log odds of laying eggs	0.767c	−0.028	−0.795

log-likelihood ratio test	1.386	−0.048	−1.392

p-value	0.166	0.962	0.164

Log odds of laying eggs	−1.952	−3.312	−1.36

log-likelihood ratio test	−2.398	−3.805	−2.276

p-value	0.016	<0.001	0.023

Log odds of laying eggs	−1.161	−2.496	−1.335

log-likelihood ratio test	−1.613	−3.486	−2.534

p-value	0.107	<0.001	0.011

Log odds of laying eggs	1.121	0.359	−0.762

log-likelihood ratio test	1.557	0.465	−1.218

p-value	0.120	0.642	0.223


Sample	Layer thickness [nm] mean ± standard deviation

NCO-sP(EO-stat-PO) sample1	19.6 ± 0.4

NCO-sP(EO-stat-PO) sample2	24.4 ± 1.0

NCO-sP(EO-stat-PO) sample3	12.0 ± 0.8


Doped Atoms X	Concentration (%)	Band Gap (eV)	CBM	VBM

-	0.00	1.59	Γ	Γ

S	1.56	1.52	Γ	Γ

S	2.78	1.48	Γ	Γ

S	6.25	1.43	Γ	Γ

O	6.25	1.54	Y	Γ

Te	6.25	1.39	Γ	Γ

Doped Atoms X	Concentration (%)	Band Gap (eV)	CBM	VBM

-	0.00	1.59	Γ	Γ

S	1.56	1.52	Γ	Γ

S	2.78	1.48	Γ	Γ

S	6.25	1.43	Γ	Γ

O	6.25	1.54	Y	Γ

		1	Γ	Γ

Doped Atoms X	Concentration (%)	Band Gap (eV)

Te	6.25	.39


PAHs	Percentage (%)	PAHs	Percentage (%)

	Urban/agricultural soil	Forest soil		Urban/agricultural soil	Forest soil

Naphthalene	0.60-16.20	0.38-1.95	Benzo [a] anthracene	5.81-8.30	5.29-8.06


Clinical Characteristics	Mean (±SD) or Frequency(%)

Mean Age in years	34.1±13.01

Sex

 Males	126 (60.3%)

 Females	83 (39.7%)

Location of pain

 Flank Pain	156 (75.4%)

 Costovertebral angle pain	53 (24.6%)

Radiation

 None	85 (48.8%)

 Front	64 (30.6%)

 Groin	50 (23.9%)

 Genitalia	10 (4.7%)

Onset of pain

 Sudden	100 (47.8%)

 Gradual	109 (52.2%)

Severity of pain

 Mild to Moderate	133 (63.6%)

 Severe	76 (36.4%)

Pain Character

 Colicky	122 (58.4%)

 Continuous	87 (41.6%)

Urinary symptoms

 None	56 (26.8%)

 Dysuria	99 (47.4%)

 Frequency/urgency	39 (18.7%)

 Hematuria	15 (7.2%)

Systemic symptoms

 None	90 (43.1%)

 Nausea, vomiting	109 (52.2%)

 Fever	10 (4.7%)

Aggravating factors

 None	111 (53.1%)

 Movement	67 (32.1%)

 Rest	31 (14.8%)

Past history of renalstones

 Yes	60 (28.8%)

 No	149 (71.2%)

Findings on examination

 None	152 (72.7%)

 Costovertebral angle tenderness	57 (27.3%)


Primary site	N	HR

CUP (reference)	2881	1

Colorectal cancer	1438	0.61

Pancreatic cancer	460	1.71

Stomach cancer	322	1.16

Liver cancer	188	1.58

Lung cancer	2453	0.98

Kidney cancer	284	0.71

Bladder cancer	139	0.93

Prostate cancer	1259	0.24

Breast cancer	202	0.53

All known primaries	6745	0.69


	Cedrela	Cordia	Swietenia	Tabebuia

abeuia	0834	.0023	.4700	0


Patients presenting to a hospital with hip fracture (N = 78)	Admitted, n (%)	Not admitted, n (%)

Age (in years)	50–59	7 (26)	15 (29)


IBDelphi	PLINK (all)	King robust (all)	PLINK (by pop.)	King homo (by pop.)


 	Tested in past 12 m	Not tested in past 12 m	P*

Overall number of subjects (N = 349**)	260	89

Facilitators by code**

Health concerns for self or others	65 (15.4)	12 (12.5)	0.47

 Perceived risk	15 (3.6)	3 (3.1)	0.83

 Lab characteristic	15 (3.6)	3 (3.1)	0.83

 Access to transportation	36 (8.6)	11 (11.5)	0.37

 Mobile testing center/SEP	75 (17.8)	13 (13.5)	0.31

 Adequate time	9 (2.1)	4 (4.2)	0.25

 Knowledge of testing	25 (6.7)	9 (9.4)	0.22

 Free testing	85 (20.2)	13 (13.5)	0.13

 Access to MD/PCP	28 (6.7)	5 (5.2)	0.60

 Not having to take initiative	5 (1.2)	0 (0)	0.28

 Rapport with provider	10 (2.4)	2 (2.1)	0.86

 Confidentiality	8 (1.9)	1 (1.0)	0.56

 Motivation	5 (1.2)	1 (1.0)	0.90

 Other	16 (3.8)	8 (8.3)	0.06

 Nothing	24 (5.7)	11 (11.5)	0.04


Identification	Description of the gene	Primers	Primer efficiency

A-E4	Mitogen-activated protein kinase	F: 5′- GAAGATGAGAAACCACAAGCG	90 %

R: 5′- CATTCTGAGGAACTTGGAGAGG

C-G1	Importin subunit alpha1a	F: 5′- GAACTCATTTTGTGCCCCATC	92 %

R: 5′- GCTGAGGGATTGGAAAAGATTG

E188	Intracellular Ras-group-related LRR protein 9	F: 5′- GAGAGGCAGGATTGGAGATTG	94 %

R: 5′- TCCGCATCCTTCAACATCTTC

E-E3	Polyadenylate-binding protein RBP47	F: 5′- TCCTAATGAGCCTAACAAACCTG	92 %

R: 5′- TCCGTCTTATTGCCTTCCAC

VHA-A1	V-ATPase catalytic subunit A1	F: 5’- CGAGAAGGAAAGCGAGTATGG	107 %

R: 5’- TCATTCACCATCAGACCAGC

B-D5	Vacuolar H + -ATPase V0 sector	F: 5′- GCAGTCATTATCAGTACCGGG	89 %

R: 5′-TCTAACACCAGCATCACCAAC

B-E2	Pectin acetylesterase	F: 5’-CACACCCACAAAGAGAAACAG	103 %

R: 5’-TTCCAAGAATGCCCCTTCAG

12.	XTH	F: 5’-AGAGGTGGGCTTGAGAAAAC	93 %

R: 5’-GAACCCAACGAAGTCTCCTATAC

B-D9	26S proteasome	F: 5’-TCTTGTCCTCTTTCTGTTCCTTATC	95 %

R: 5’-AATCCTTGCCTCACTTCCAG

C-A3	Histone H2B	F: 5′- TTGGTAACAGCCTTAGTTCCTC	89 %

R: 5′- AAAGCCTACCATCACTTCTCG

PP2ACS	PROTEIN PHOSPHATASE 2A catalytic subunit	F: 5’- CGATGTGTGATCTCCTATGGTC	98 %

R: 5’- AAGCTGATGGGCTCTAGAAATC

Identification	Description of the gene

A-E4	Mitogen-activated protein kinase

C-G1	Importin subunit alpha1a

E188	Intracellular Ras-group-related LRR protein 9

E-E3	Polyadenylate-binding protein RBP47

VHA-A1	V-ATPase catalytic subunit A1

B-D5	Vacuolar H + -ATPase V0 sector

B-E2	Pectin acetylesterase

12.	XTH

B-D9	26S proteasome

C-A3	Histone H2B

PP2ACS	PROTEIN PHOSPHATASE 2A catalytic subunit

Primers	Primer efficiency

F: 5′- GAAGATGAGAAACCACAAGCG	90 %

R: 5′- CATTCTGAGGAACTTGGAGAGG

F: 5′- GAACTCATTTTGTGCCCCATC	92 %

R: 5′- GCTGAGGGATTGGAAAAGATTG

F: 5′- GAGAGGCAGGATTGGAGATTG	94 %

R: 5′- TCCGCATCCTTCAACATCTTC

F: 5′- TCCTAATGAGCCTAACAAACCTG	92 %

R: 5′- TCCGTCTTATTGCCTTCCAC

F: 5’- CGAGAAGGAAAGCGAGTATGG	107 %

R: 5’- TCATTCACCATCAGACCAGC

F: 5′- GCAGTCATTATCAGTACCGGG	89 %

R: 5′-TCTAACACCAGCATCACCAAC

F: 5’-CACACCCACAAAGAGAAACAG	103 %

R: 5’-TTCCAAGAATGCCCCTTCAG

F: 5’-AGAGGTGGGCTTGAGAAAAC	93 %

R: 5’-GAACCCAACGAAGTCTCCTATAC

F: 5’-TCTTGTCCTCTTTCTGTTCCTTATC	95 %

R: 5’-AATCCTTGCCTCACTTCCAG

F: 5′- TTGGTAACAGCCTTAGTTCCTC	89 %

R: 5′- AAAGCCTACCATCACTTCTCG

F: 5’- CGATGTGTGATCTCCTATGGTC	98 %

R: 5’- AAGCTGATGGGCTCTAGAAATC


SCG Feature Point	AS	MC

mean	1.04	1.41

± SD	0.7	0.5


Time (d)	Number of identified proteinsa	Number of secreted proteinsb (percentage of identified proteins)

0	89	31 (35 %)

7	1009	150 (15 %)

14	1077	163 (15 %)

21	1149	170 (15 %)

28	1151	170 (15 %)

42	1035	157 (15 %)

Time (d)	Number of identified proteinsa	Number of secreted proteinsb (percentage of identified proteins)

0	89	31 (35 %)

7	1009	150 (15 %)

14	1077	163 (15 %)

	11	17

Time (d)	Number of identified proteinsa	Number of secreted proteinsb (percentage of identified proteins)

21	49	0 (15 %)

28	1151	170 (15 %)

42	1035	157 (15 %)


	Tested N = 3810	Untested N = 904	p-value

	n (%)	n (%)


County

Area (km2)a	1290.835

Year	1996–1998

Population (person)a	752,427

Number of large manufacturingb	35

Agricultural land (Hectare)c	112,870

Number of doctors (/1000 people)a	0.66

Number of hospital (/1000 people)a	0.031

Life expectancy at birth	74.05

Life expectancy at 5 years old	69.74

Life expectancy at 65 years old	15.98

Mortality rate (/10000)	671.41


	N (%)

Surgical resection

 Yes/no	13 (25)/40 (75)

 Margin: R0/R1	10 (19)/3 (6)

Type of surgery

 Liver resection	3 (6)

 CRS and HIPEC	5 (9)

 Primary tumor resection and liver resection	3 (6)

 Primary + CRS and HIPEC1	1 (28)

 Lung resection	1 (2)

	N (%)

Yes/no	13 (25)/40 (75)

Margin: R0/R1	10 (19)/3 (6)

Type of surgery

Liver resection	3 (6)

CRS and HIPEC	5 (9)

Primary tumor resection and liver resection	3 (6)

Primary + CRS and HIPEC1	1 (28)

Lung resection	1 (2)


Authors	Population	Outcome parameters	Validity	Quality	Quantity	Activity

Dobkin et al. [33]	Stroke	Walking speed, bouts of walking, gait symmetry	Leave-one-subject-out method	-	x	Walking

Zampieri et al. [44]	PD	Stride length, stride velocity, cadence, peak arm swing velocity on the MAS, and turning velocity	Leave-one-subject-out method	-	x	Sitting, standing, walking, turning

Mizuike et al. [37]	Stroke	Accelerometers derivatives, raw RMS, normalized RMS, autocorrelation function	Cross-validation	x	x	Walking

Prajapati et al. [40]	Stroke	Walking bouts, total walking time, gait speed, number of steps, gait symmetry, swing symmetry, cadence	Cross-validation	x	-	Walking

Authors	Population	Outcome parameters	Validity

Dobkin et al. [33]	Stroke	Walking speed, bouts of walking, gait symmetry	Leave-one-subject-out method

Zampieri et al. [44]	PD	Stride length, stride velocity, cadence, peak arm swing velocity on the MAS, and turning velocity	Leave-one-subject-out method

Mizuike et al. [37]	Stroke	Accelerometers derivatives, raw RMS, normalized RMS, autocorrelation function	Cross-validation

Prajapati et al. [40]	Stroke	Walking bouts, total walking time, gait speed, number of steps, gait symmetry, swing symmetry, cadence	Cross-validation

Quality	Quantity	Activity

-	x	Walking

-	x	Sitting, standing, walking, turning

x	x	Walking

x	-	Walking


Statement	N	Mean [Range]

Feel supported in carrying out my work at the clinic	20	4.05 [2-5]

Feel confident when carrying out my work at the clinic	20	4.65 [4-5]

Feel the work I do is important and well valued	20	4.55 [2-5]

Find the work load at the clinic is too demanding	20	3.3 [2-5]

The facilities at the KCC clinic are adequate for me to carry out my work	20	2.65 [1-5]

Work at KCC is stressful	20	2.3 [1-5]

Training that I have undertaken has improved my skills	20	4.7 [4-5]

Training has improved the knowledge	20	4.4 [4-5]

Quality of care I provide has improved	20	4.6 [4-5]

Each patient is given the right amount of time	20	3.45 [2-5]

Statement	N	Mean [Range]

Find the work load at the clinic is too demanding	20	3.3 [2-5]

The facilities at the KCC clinic are adequate for me to carry out my work	20	2.65 [1-5]

Work at KCC is stressful	20	2.3 [1-5]

Training that I have undertaken has improved my skills	20	4.7 [4-5]

Training has improved the knowledge	20	4.4 [4-5]

Quality of care I provide has improved	20	4.6 [4-5]

Each patient is given the right amount of time	20	3.45 [2-5]


Disease	Gene	Inheritance mode	Other clinical features (main)

Monogenic diseases causing small artery occlusion (lacunar) ischemic stroke

 CADASIL [78]	NOTCH3	autosomal dominant	migraine with aura, mood disturbance, progressive cognitive impairment

 CARASIL [79, 80]	HTRA1	autosomal recessive	alopecia, dementia, gait disturbance, low back pain, mood disturbance

 RVCL [81–84]	TREX1	autosomal dominant	visual loss, stroke, dementia, seizures, headache, personality disorders

Monogenic diseases causing large artery and small artery occlusion (lacunar) ischemic stroke

 Sickle cell disease [85, 86]	HBB	autosomal recessive	more seldom hemorrhagic stroke, vaso-occlusive or painful crisis, retinopathy, chronic leg ulcers, increased susceptibility to infection, anemia

 Homocystinuria [87, 88]	CBS*	autosomal recessive*	thromboembolism, mental retardation, ectopia lentis, skeletal abnormalities

 Fabry disease [89–91]	GLA	X-linked	acroparesthesia, hypohidrosis, angiokeratoma, chronic kidney disease, cardiomyopathy

 PXE [92–94]	ABCC6	autosomal recessive	peau d’orange lesions, ocular complications, hypertension, peripheral artery disease, coronary artery disease, gastrointestinal bleeding

Monogenic diseases causing ischemic stroke of other etiologies

 Vascular EDS [95–98]	COL3A1	autosomal dominant	dissection and rupture of arteries, rupture or hollow organs, easy bruising, thin skin with visible veins

 Marfan syndrome [99–102]	FBN1*	autosomal dominant	aortic root dilatation and dissection, ectopia lentis, marfanoid habitus, dural ectasia, pneumothorax

Monogenic mitochondrial disorders

 MELAS [103–105]	tRNA Leu	maternal inheritance	seizures, recurrent headaches, anorexia, recurrent vomiting, myopathy with exercise intolerance

Monogenic diseases causing intracerebral hemorrhage

 CAA [106–110]	APP, CST3	autosomal dominant	dementia, transient neurological symptoms and seizures

 COL4A1 syndrome [111–115]	COL4A1	autosomal dominant	more seldom lacunar ischemic stroke, porencephaly, intracranial aneurysms, retinal arteriolar tortuosities and haemorrhage, cataract, Axenfeld-Rieger syndrome, hematuria, renal cysts, mild renal failure, muscle cramps


Group; cases	Dc, mm	Dc, mean ±SD, mm	Age, mean ± SD, y	Body mass index, mean ± SD, kg/m2	Rate of expansion, mean ± SD

1; N = 16	Dc = 0	0.0 ± 0.0	45.6 ± 9.8	19.5 ± 1.8	1.3 ± 0.1

2; N = 24	0 < Dc < 10	4.0 ± 2.2	47.3 ± 10.3	21.9 ± 2.5	1.4 ± 0.2

Group; cases	Dc, mm	Dc, mean ±SD, mm	Age, mean ± SD, y	Body mass index, mean ± SD, kg/m2	Rate of expansion, mean ± SD

3; N = 10	10 ≤ Dc	13.2 ± 3.7	53.6 ± 10.4	22.7 ± 1.8	1.5 ± 0.2


Mangifera indica L.Nutrition value per 100 g

Energy	60 Kcal

Fruit composition	Quantity

Carbohydrates	14.98 g

Protein	0.82 g

Fat	0.38 g

Fiber	1.6 g

Vitamins

Vitamin C	36.4 mg

Vitamin E	1.12 mg

Vitamin A	1082 IU

Niacin (vit B3)	669 μg

Pantothenic acid (vit B5)	160 μg

Pyridoxine (vit B6)	119 μg

Riboflavin (vit B2)	38 μg

Thiamin (vit B1)	28 μg

Folates	43 μg

Vitamin K	4.2 μg

Minerals

Potassium	168 mg

Phosphorus	14 mg

Calcium	11 mg

Magnesium	10 mg

Sodium	1 mg

Copper	110 μg

Iron	160 μg

Manganese	27 μg

Zinc	90 μg

Carotenoids

β−Carotene	445 μg

α−Carotene	17 μg

Mangifera indica L.Nutrition value per 100 g

Vitamin E	1.12 mg

Vitamin A	1082 IU

Niacin (vit B3)	669 μg

Pantothenic acid (vit B5)	160 μg

Pyridoxine (vit B6)	119 μg

Riboflavin (vit B2)	38 μg

Thiamin (vit B1)	28 μg

Folates	43 μg

Vitamin K	4.2 μg

Minerals

Potassium	168 mg

Phosphorus	14 mg

Calcium	11 mg

Magnesium	10 mg

Sodium	1 mg

Copper	110 μg

Iron	160 μg

Manganese	27 μg

Zinc	90 μg

Carotenoids

β−Carotene	445 μg

α−Carotene	17 μg


Cultivar (cv.)	Number of samples	Geographical origin

Coratina	10	Bari (Apulia, Italy)

Ogliarola Garganica	10	Gargano, Foggia (Apulia, Italy)

Ogliarola Barese	10	Bari (Apulia, Italy)

Cima di Mola	10	Bari (Apulia, Italy)

Picholine	10	Bari (Apulia, Italy)

Peranzana	3	San Severo, Foggia (Apulia, Italy)

Carolea	8	Calabria

Rossanese	3	Calabria

Picual	3	Spain

Kalamata	3	Greece

Koroneiki	3	Greece

Cultivar (cv.)	Number of samples

Coratina	10

Ogliarola Garganica	10

Ogliarola Barese	10

Cima di Mola	10

Picholine	10

Peranzana	3

Carolea	8

Rossanese	3

Picual	3

Kalamata	3

Koroneiki	3

Geographical origin

Bari (Apulia, Italy)

Gargano, Foggia (Apulia, Italy)

Bari (Apulia, Italy)

Bari (Apulia, Italy)

Bari (Apulia, Italy)

San Severo, Foggia (Apulia, Italy)

Calabria

Calabria

Spain

Greece

Greece


Workflow A	Workflow B	Workflow C

+ ease of application	+ very straightforward, no parameters or thresholds	+ can integrate many existing programs

+ software is available	+ guaranteed result in several rounds	+ different algorithms address particular properties of promoters

+ the spectrum of existing methods covers all particular aspects of transcriptional regulation	 	+ optimization of a collection of combinatorial modules instead of optimization of each module separately

– big number of methods to choose from (over 150 can be found in the Internet)	– may lead to a scission of a functional module rendering all parts non functional	– huge number of predicted features require much memory and CPU = > specificity filtering should be applied before modules optimization

– relative performance of methods differs for different datasets	– high lab work and time investments

– chance of a correct prediction is ~5-10% [5]

– impossible to estimate the number of required rounds

Workflow A	Workflow B	Workflow C

+ ease of application	+ very straightforward, no parameters or thresholds	+ can integrate many existing programs

+ software is available	+ guaranteed result in several rounds	+ different algorithms address particular properties of promoters

+ the spectrum of existing methods covers all particular aspects of transcriptional regulation		+ optimization of a collection of combinatorial modules instead of optimization of each module separately

– big number of methods to choose from (over 150 can be found in the Internet)	– may lead to a scission of a functional module rendering all parts non functional	– huge numbe

– relative performance of methods differs for different dat	– high lab

Workflow A	Workflow B	Workflow C

asets	 work and time investments	r of predicted features require much memory and CPU = > specificity filtering should be applied before modules optimization

– chance of a correct prediction is ~5-10% [5]

– impossible to estimate the number of required rounds


First author	Year	Ethnicity	Disease	Sample	Number	Gender (M/F)	Age (years)	Method	NOS score

Tumor	Benign	Normal

Longo [29]	2014	Caucasians	HNSCC	Tissue	96	0	79	75/21	59 (20~90)	qMSP	8

Liu [28]	2013	Asians	CC	Tissue	40	0	40	0/40	—	MSP	6

Weiss [10]	2011	Caucasians	HNSCC	Tissue	49	0	31	—	63.7 ± 11.8	MSP	7

Yang [9]	2010	Caucasians	CC	Tissue	60	40	20	—	46 (38~57) 	qMSP	7

Yanatatsaneejit [20]	2008	Asians	NPC	Tissue	46	0	20	—	—	Duplex MSP	6

Brait [5]	2008	Caucasians	BCa	Tissue	93	0	26	—	67 (39~83)	qMSP	8

25	0	5	—	66 (34~84)	qMSP

Yu [21]	2003	Asians	BCa	Tissue	132	23	0	107/25	—	MSP	8

Kitkumthorn [19]	2006	Asians	CC	Tissue	30	24	25	—	—	Duplex MSP	6

Tokumaru [12]	2004	Asians	HNSCC	Tissue	20	0	11	—	—	MSP	6

Yu [21]	2003	Asians	HCC	Tissue	28	0	28	—	—	MSP	6

Brait [5]	2008	Caucasians	BCa	Tissue	25	0	5	—	66 (34~84)	qMSP	8

Yu [21]	2003	Asians	BCa	Tissue	132	23	0	107/25	—	MSP	8

Kitkumthorn [19]	2006	Asians	CC	Tissue	30	24	25	—	—	Duplex MSP	6

Tokumaru [12]	2004	Asians	HNSCC	Tissue	20	0	11	—	—	MSP	6

Yu [21]	2003	Asians	HCC	Tissue	28	0	28	—	—	MSP	6


	Migraine in AH-group	Migraine in Non-AH group	Total

Females	6 (50 %)	48 (33 %)	54 (34 %)

Males	1 (11 %)	7 (8 %)	8 (8 %)

Total	7 (33 %)	55 (24 %)	62 (24 %)


Plants	Colony forming units at 600 mg/ml	Colony forming units at 450 mg/ml

10 (min)	20 (min)	40 (min)	0 minutes (ctrl)	10 (min)	20 (min)	40 (min)	0 minutes (ctrl)

S. aculeastrum	5.00 ± 1.70b	4.00 ± 1.70ab	4.00 ± 1.70a	43 ± 1.70c	5.00 ± 1.60b	4.00 ± 1.60ab	4.00 ± 1.60a	43 ± 1.60c


	30 bp VNTR			941 G/T

	Allele			Allele

	2R	3R	4R	5R	Short (2R, 3R)	Long (4R, 5R)	G	T

Transm		5	3		5		5	3


 	T. muris L1 assay	Adult T. muris assay

Duration of drug assaya	24 hours	72 hours

Number of parasites per well	20 to 200	2 to 4

Dissection of animal host required	No	Yes

Subjective analysis	Yes	Yes

Viability marker alternative	No	Yesb

Total operational hours	3.5 hoursc	6.5 hoursd

Applicability to high-throughput screening	No	No

	T. muris L1 assay	Adult T. muris assay

Duration of drug assaya	24 hours	72 hours

Number of parasites per well	20 to 200	2 to 4

Dissection of	No

 animal host required		Yes

Subjective analysis	Yes	Yes

Viability marker alternative	No	Yesb

Total operational hours	3.5 hoursc	6.5 hoursd

Applicability to high-throughput screening	No	No


	Sense	Antisense

Reference gene

 Gapdh	5′-ggcaaattcaacggcaca-3′	5′-gttagtggggtctcgctcctg-3′

Inflammation marker

 S100A8	5′-tgtcctcagtttgtgcagaatataaat-3′	5′-tttatcaccatcgcaaggaactc-3′

 S100A9	5′-ggcaaaggctgtgggaagt-3′	5′-ccattgagtaagccattcccttta-3′

Mobilization markers

 CCL2	5′-ttggctcagccagatgca-3′	5′-cctactcattgggatcatcttgct-3′

 CX3CL1	5′-gtgccattgtcctggagac-3′	5′-catttctccttcgggtcag-3′

 KC	5′-tggctgggattcacctcaa-3′	5′-gagtgtggctatgacttcggttt-3′

 MIP-1α	5′-caagtcttctcagcgccatatg-3′	5′-tcttccggctgtaggagaagc-3′

Cell markers

 CX3CR1	5′-gagtatgacgattctgctgagg-3′	5′-cagaccgaacgtgaagacgag-3′

 CCR2	5′-ctatctgctcaacttggccatct-3′	5′-tgagcccagaatggtaatgtga-3′

 Ly6C	5′-gcagtgctacgagtgctatgg-3′	5′-actgacgggtctttagtttcctt-3′

 F4/80	5′-aatcctgtgaagatgtgg-3′	5′-gagtgttgatgcaaatgaag-3′

Adhesion molecules

 LFA1	5′-gaatgtatgaagggcaaagtc-3′	5′-gcagcaaactggtaggaag-3′

 VCAM	5′-ccaagtctctccaaaagatatacagctt-3′	5′-atgacggtgtctccctct-3′

 L-selectin	5′-actgctctgttgtgacttcc-3′	5′-tgtatggcgactaaatctgtg-3′

 PECAM1	5′-tccctgggaggtcgtccat-3′	5′-gaacaaggcagcggggttta-3′

 VE-cadherin	5′-tcctcttgcatcctcactatcaca-3′	5′-gtaagtgaccaactgctcgtgaat-3′


locus	primer	source	sequence

COI	LCO_Hym (C1-J-1514)	[75]	5'-TATCAACCAATCATAAAGATATTGG-3'

	C1-J-1580	new	5'-ACATCTTTAAGAATAATTATTCG-3'

	Nancy-short (C1-N-2194)	[76]	5'-CCCGGTAAAATTAAAATATAAAC-3'

	Pat (TL2-N-3014)	[76]	5'-TCCAATGCACTAATCTGCCATATTA-3'

28S	28S for (D2-3665F)	[82]	5'-AAGAGAGAGTTCAAGAGTACGTG-3'

	28Srev (D3-4283R)	[82]	5'-TAGTTCACCATCTTTCGGGTCCC-3'

TPI	L1F	[83]	5'-CTKCGTBGGNGGNAACTGGAAGATGA-3'

	L1R	[83]	5'-CCRATRGCCCANACNGGYTCRTA-3'


Range(mA)	Heaterresistance (Ω)	Thermocoupleresistance (Ω)	Output emf(mV)	Reversalerror (μA/A)	Timeconstant (s)

5	50 to 60	8 to 13	11	50	<2

10	30 to 40	7 to 8	9	220	<2

20	20 to 25	3 to 5	9	250	<2

30	6 to 7	3 to 5	9	240	<2

50	3 to 4	3 to 5	9	100	<2

100	1 to 2	3 to 5	10	140	<2

250	0.5 to 1.0	2 to 4	11	130	<3


	PEF (L/s)

Control	0.68 ± 0.28

Treadmill	1.68* ± 0.51

Flutter®	1.53* ± 0.25


 	0 additional risk	1 additional risk	2 additional risk	3 additional risk	4 additional risk

Physical Activity Risk

No	88	223	211	114	30

Yes	168	591	815	481	157


Code	Value	%agea	Description

J	140	7.28	Translation

A	0	0	RNA processing and modification

K	101	5.25	Transcription

L	128	6.66	Replication, recombination and repair

B	1	0.05	Chromatin structure and dynamics

D	24	1.25	Cell cycle control, mitosis and meiosis

Y	0	0	Nuclear structure

V	47	2.45	Defense mechanisms

T	62	3.23	Signal transduction mechanisms

M	66	3.43	Cell wall/membrane biogenesis

N	5	0.26	Cell motility

Z	0	0	Cytoskeleton

W	0	0	Extracellular structures

U	26	1.35	Intracellular trafficking and secretion

O	56	2.91	Posttranslational modification, protein turnover, chaperones

C	79	4.11	Energy production and conversion

G	40	2.08	Carbohydrate transport and metabolism

E	137	7.13	Amino acid transport and metabolism

F	61	3.17	Nucleotide transport and metabolism

H	58	3.02	Coenzyme transport and metabolism

I	41	2.13	Lipid transport and metabolism

P	77	4.01	Inorganic ion transport and metabolism

Q	15	0.78	Secondary metabolites biosynthesis, transport and catabolism

R	179	9.31	General function prediction only

S	133	6.92	Function unknown

-	554	28.82	Not in COGs

Code	Value	%agea	Description

J	140	7.28	Translation

A	0	0	RNA processing and modification

K	101	5.25	Transcription

L	128	6.66	Replication, recombination and repair

B	1	0.05	Chromatin structure and dynamics

D	24	1.25	Cell cycle control, mitosis and meiosis

Y	0	0	Nuclear structure

V	47	2.45	Defense mechanisms

T	62	3.23	Signal transduction mechanisms

M	66	3.43	Cell wall/membrane biogenesis

N	5	0.26	Cell motility

Z	0	0	Cytoskeleton

W		0	Extracellular structure

	0		s

U	26	1.35	Intracellular trafficking and secretion

O	56	2.91	Posttranslational modification, protein turnover, chaperones

C	79	4.11	Energy production and conversion

G	40	2.08	Carbohydrate transport and metabolism

E	137	7.13	Amino acid transport and metabolism

F	61	3.17	Nucleotide transport and metabolism

H	58	3.02	Coenzyme transport and metabolism

I	41	2.13	Lipid transport and metabolism

P	77	4.01	Inorganic ion transport and metabolism

Q	15	0.78	Secondary metabolites biosynthesis, transport and catabolism

R	179	9.31	General function prediction only

S	133	6.92	Function unknown

-	554	28.82	Not in COGs


	GT1M	GT3X	Actitrainer

Belgium (n = 109)	0%	96%	4%


Response	N	%

Nothing would happen	34	30.1

My Doctor (the researcher) would not be happy with me	10	8.8

I don't know	8	7.1

Could be a bad decision for me clinically	38	33.6

Others	23	20.4

"I might regret not utilizing the opportunity for the free treatment"

"How can I stop participation when I have come to seek medical help?"

"I would discourage others who want to join"

"I would spoil their work."

"It is compulsory"

"It shows that there is no reason for my coming"

"It is a research work, I can't stop"

"I would be insulting the Doctors by stopping"

"I would have cheated myself"

"It shows that I'm not serious"

"I can't stop because Doctor is doing something good"

"I would go back with the problem I came with"

"Doctor would go away"

"I can't say I would stop participation since I chose to come for my health sake"

"My conscience would not allow me because it is helpful"

"I want to know what they are doing" etc

Response	N	%

	3	20.4

"I might regret not utilizing the opportunity for the free treatment"

"How can I stop participation when I have come to seek medical help?"

"I would discourage others who want to join"

"I would spoil their work."

"It is compulsory"

"It shows that there is no reason for my coming"

"It is a research work, I can't stop"

"I would be insulting the Doctors by stopping"

"I would have cheated myself"

"It shows that I'm not serious"

"I can't stop because Doctor is doing something good"

"I would go back with the problem I came with"

"Doctor would go away"

"I can't say I would stop participation since I chose to come for my health sake"

"My conscience would not allow me because it is helpful"

"I want to know what they are doing" etc


Group	Surgery time* (mean ± SD)	Extubation time* (mean ± SD)

TRA	95.3 ± 17.4	6.6 ± 2.4

MET 0.5	98.2 ± 15.2	7.2 ± 1.6

MET 0.7	98.5 ± 12.8	7.3 ± 2.2


		Median ± SD of PRB expression (2^-∆Ct)

PRB status at day 1	Day 1	Day 15

Control group	PRB+	0.014 ± 0.01	0.010 ± 0.02

PRB-	0.007 ± 0.00	0.007 ± 0.001

Treated group	PRB+	0.014 ± 0.01	0.011 ± 0.01

PRB-	0.006 ± 0.002	0.006 ± 0.003


Drug	Brain disease	Mechanism	Reference

ω-3 PUFA	ADHD	Nonspecific antioxidant effect	[151, 152]

Vitamin C	Vascular dementia	Free radical scavenger	[153]

Hyperbaric O2	Autism	Anti-inflammatory and reduces oxidative stress	[157]

H2S	Focal cerebral ischemia/reperfusion	Inhibits oxidative phosphorylation, inflammation, and apoptosis	[159]

H2-rich saline	Focal or global cerebral ischemia/reperfusion	Reduces oxidative stress and inflammation	[160, 161]

Lithium	Healthy volunteers	Prevents/or reverses DNA damage, lipid peroxidation, and free radical formation	[164]

Pifithrin-μ	Perinatal hypoxic-ischemic brain damage	Inhibition of the apoptotic pathways and reduction of the oxidative stress	[166]

Telmisartan	Vascular dementia	Anti-inflammatory and antioxidant effects	[174–176]

Nanodrugs	 	ROS scavengers	[177]

Triterpenoids	Parkinson	Antioxidants via Nrf2/ARE pathway	[146]

PPARgamma agonists	Neurodegenerative diseases	Anti-inflammatory	[162–164]

Drug	Brain disease	Mechanism

ω-3 PUFA	ADHD	Nonspecific antioxidant effect

Vitamin C	Vascular dementia	Free radical scavenger

Hyperbaric O2	Autism	Anti-inflammatory and reduces oxidative stress

H2S	Focal cerebral ischemia/reperfusion	Inhibits oxidative phosphorylation, inflammation, and apoptosis

H2-rich saline	Focal or global cerebral ischemia/reperfusion	Reduces oxidative stress and inflammation

Lithium	Healthy volunteers	Prevents/or reverses DNA damage, lipid peroxidation, and free radical formation

Pifithrin-μ	Perinatal hypoxic-ischemic brain damage	Inhibition of the apoptotic pathways and reduction of the oxidative stress

Telmisartan	Vascular dementia	Anti-inflammatory and antioxidant effects

Nanodrugs		ROS scavengers

Triterpenoids	Parkinson	Antioxidants via Nrf2/ARE pathway

PPARgamma agonists	Neurodegenerative diseases	Anti-inflammatory


Main Reason for Being Here	Frequency	Percent

Fracture	6	12.8

Strain, sprain, dislocation	7	14.9

Cut, bite, penetrating injury, open wound	19	40.4

Bruise, scrape, superficial wound	9	19.1

Concussion, closed head injury	2	4.3

Organ system injury/multiple organ injury	2	4.3

Other	1	2.1

Unknown	1	2.1

Total	47	100.0

Main Reason for Being Here

Fracture

Strain, sprain, dislocation

Cut, bite, penetrating injury, open wound

Bruise, scrape, superficial wound

Concussion, closed head injury

Organ system injury/multiple organ injury

Other

Unknown

Total


Comparison of number of knots along the sessions between loop & winding method

	S1		S		S5


Weeks of Treatment

0

5

6

7

8

9

10

11

12

Mean


No of isolates	Locus	Fragment length (bp)	No. of alleles	Gene diversity ± SD	No. of polymorphic sites	Avg. number of nucleotide differences	Nucleotide diversity ± SD


Predictors	Regression coefficient	Odds ratio	95% CI	Risk score = Regression coefficient × 25

Pre-existing diseases (CCI >3)	2.02	7.52	2.01 to 28.1	50.5

Parent to children <18 years	1.26	3.51	1.39 to 8.89	31.5

Previous psychological problems	1.14	3.13	1.12 to 8.76	28.5

In-ICU agitation	0.8	2.23	-0.80 to 6.22	20

Unemployed/sick-leave at ICU admission	0.48	1.62	-0.54 to 4.88	12

Appeared depressed in ICU	0.30	1.35	-0.55 to 3.31	7.5


Cisplatin concentration	Apoptosis level

0.0	0.0

0.0001	0.0

0.001	5E-6

0.01	4.67E-4

Cisplatin concentration	Apoptosis level

0.1	2.96E-2

0.5	0.16

1.0	0.23


Measure	Outcome results

Maternal

 Dams’ daily mean fluid consumption (mL/day)

For 14 days before mating	14.7 ± 0.8

During gestation	29.5 ± 1.8

PND1–PND10	46.8 ± 3.7

 Dams’ weight (g)

14 days before mating	223 ± 6

At mating	247 ± 7

Total weight gain during pregnancy	127 ± 6

 Mating success rate (%)	93.8 ± 1.2

Litter and physical milestones

 Length of gestation (days)	20.5 ± 0.2

 Mean litter size (pups)	11.9 ± 0.4

 Sex distribution at birth [male/female (%)]	54/46

 Litter mortality (dead newborn pups/litter)	0.2 ± 0.1

 Pup mortality during lactation (%)	1.9 ± 0.1

 Eye opening [male/female (%)]

At PND14, one or both eyes	78 ± 5/75 ± 6

At PND16, both eyes	100/100

Female offspring body weight (g)

 At birth (PND0)	6.12 ± 0.14

 PND10	20.3 ± 1.2

 PND21	50.1 ± 2.1

 PND90	254.6 ± 4.8


Number	Compound	tR (min)	HR-L	HR-D	SR

mg g−1 DW	mg g−1 DW	mg g−1 DW

1	3-O-Caffeoylquinic acid	4.0	0.06 (4.80)a	—	0.70 (0.34)b

2	5-O-Caffeoylquinic acid	7.4	5.12 (2.24)b	1.96 (2.92)a	18.26 (0.46)c

3	4-O-Caffeoylquinic acid	8.1	0.12 (5.03)b	0.06 (2.35)a	0.42 (0.95)c

4	1,3-Di-O-caffeoylquinic acid	10.2	0.22 (3.90)b	0.12 (2.68)a	1.21 (1.88)c

5	Quercetagetin hexoside	10.7	0.96 (1.65)	—	—

6	Quercetin hexoside	11.4	0.93 (1.71)	—	—

7	Quercetin hexoside	11.9	0.52 (0.61)	—	—

8	20-Hydroxyecdysone	12.0	—	—	5.60 (1.36)

9	Luteolin hexoside	12.1	0.27 (1.43)	—	—

10	Patuletin hexoside	12.2	0.25 (1.24)	—	—


Group	First dose (μg/kg) 30–60 min before surgery	Second dose (μg/kg) 24 h after surgery	Total dose (μg/kg)

1	0.25	0.25	0.5

2	0.5	0.5	1.0

3	0.75	0.5	1.25

4	1.0	0.5	1.5

5	1.0	1.0	2.0


Scaffold Designation	Composition

Chitosan (Ch) 1%	Gelatin (Gel) 1%	nHAp 0.25%	nCuZn Alloy 0.01%

Final Concentrations in Blend (%)

Ch/Gel	0.5	0.25	-	-

Ch/Gel/nHAp	0.5	0.25	0.0625	-

Ch/Gel/nHAp/nCuZn	0.5	0.25	0.0625	0.00025

Scaffold Designation

Ch/Gel

Ch/Gel/nHAp

Ch/Gel/nHAp/nCuZn

Composition

Chitosan (Ch) 1%	Gelatin (Gel) 1%	nHAp 0.25%	nCuZn Alloy 0.01%

Final Concentrations in Blend (%)

0.5	0.25	-	-

0.5	0.25	0.0625	-

0.5	0.25	0.0625	0.00025


	Absence of protective haplotypes	At least one protective haplotypes

Anti-MAP2694 Abs	Negative	258 (71 %)	103 (29 %)

Positive	122 (80 %)	31 (20 %)


Household characteristics	Value

% of houses with

 Land ownership	42.2

 Head of household with agriculture related occupation	18.1

 Ground water as main source of drinking water	61.8

 Piped water in own house	26.2

 Access to water seal latrine	74.7

 Wood/cow dung as main Fuel used for cooking	69.1

 Tobacco smoker in the HH	60.5

Mean (Standard Deviation) number of

 Persons per household	5.97 (2.61)

 Children ≤ 10 years per household	1.75 (1.54)

 Sleeping rooms per household	1.89 (0.98)

Household characteristics	Value

% of houses with

Land 	4

ownership	2.2

Head of household with agriculture related occupation	18.1

Ground water as main source of drinking water	61.8

Piped water in own house	26.2

Access to water seal latrine	74.7

Wood/cow dung as main Fuel used for cooking	69.1

Tobacco smoker in the HH	60.5

Mean (Standard Deviation) number of

Persons per household	5.97 (2.61)

Children ≤ 10 years per household	1.75 (1.54)

Sleeping rooms per household	1.89 (0.98)


No.	Age/sex	Etiology	Defect location	Flap dimensions (cm)	Complications

1	45/f	Trauma	Heel avulsion 	24×11	Partial graft loss at lower donor site

2	45/m	Verrucous carcinoma of heel	Heel	23×10	None

3	42/m	Trauma	Avulsion of heel and sole of midfoot	28×14	Patchy graft loss, healed within 20 days with dressings.

4	38/f	Squamous cell carcinoma of heel	Heel region	26×12	None

5	42/m	Verrucous carcinoma 	Heel region	23×10	None

6	60/m	Squamous cell carcinoma of heel	Heel region extending in to the sole	26×11	Partial graft loss at lower donor site

7	43/f	Trauma	Medial malleolus with dorsal foot region	25×10	None

8	48/m	Verrucous carcinoma	Heel region	22×10	Exposed fibula – 5 cm fibula excised and covered with left flap during final inset

9	49/f	Trauma	Medial malleolus region	21×10	None

10	38/m	Trauma	Heel with tendoachillis region	24×11	Partial graft loss at lower donor site

No.	Age/sex	Etiology	Defect location	Flap dimensions (cm)	Complications

7	43/f	Trauma	Medial malleolus with dorsal foot region	25×10	None

8	48/m	Verrucous carcinoma	Heel region	22×10	Exposed fibula – 5 cm fibula excised and covered with left flap during final inset

9	49/f	Trauma	Medial malleolus region	21×10	None

10	38/m	Trauma	Heel with tendoachillis region	24×11	Partial graft loss at lower donor site


Sleeping disturbance	20 (69.0)	11 (37.9)

Satisfaction

Favorable	19 (65.5)	27 (93.1)

A little	9 (31.0)	2 (6.9)

Not favorable	1 (3.4)	0


(1) Events were classified as related to knowledge-acquisition goals if their content fulfilled any of the following criteria and did not conflict

with the criteria for emotional goals.

(a) Knowledge-acquisition goals related to the future (if an event referred to words related to time, such as 6 months later, or in the future; the event was classified as related to knowledge-acquisition goals. There was also a wide range of non-future events which were coded as present-focused events).	e.g., “The problems in middle school math competitions became increasingly difficult in today’s classes, which stumped a number of my classmates. Only three questions were covered in the two classes, and I did still not understand the problem-solving process. I was very concerned about my future studies.”

(b) Knowledge acquisition	e.g., “This morning, I attended a project in which student volunteers taught us how to use computers face-to-face at the University of Posts and Telecommunications. The two problems that I didn’t understand before were solved. Thus, I was very happy.”

(c) An individual’s observation, understanding; learning of social survival skills through interaction with others; and inspiration for knowledge acquisition from the people around them, events, and their own life experiences.	e.g., “Today, I went to the Aging Lab at Beijing Normal University to take part in tests. It was a very happy thing and I acquired much knowledge constantly. It’s never too late to learn.”

(d) Realization of one’s own shortcomings through interaction with others and engagement in periodic self-assessment.	e.g., “The lesson on the Study on New Venture’s Creation was boring. The teacher suddenly asked, ‘What are you interested in? What do you care about?’ Then, I realized that I did not know how to answer these questions. I have spent days and months without doing anything meaningful. While listening to classmates’ answers, I was lost in thought.”

(e) Use of activities and events to provide information (reading books, etc.)	e.g., “On Friday evening, I turned on the computer and watched Tian tian Xiang shang, a famous, entertaining talk-show in China. The hosts sounded very happy. I should imitate their speech to improve my public-speaking skills.”

(2) Events were classified as related to emotional goals if their content fulfilled any of the following criteria and did not conflict

with the criteria for knowledge-acquisition goals.

(a) Emotional goals related to the present (if the event referred to words related to time, such as now, the present, and were within 6 months; the event was classified as related to emotional goals).	e.g., “On Sunday, my husband’s colleague, whom we had not seen for many years, was coming. We were all happy. They were very excited when they chatted about their time at the company.”

(b) Mood control rather than pursuit of new knowledge (emotion can be affected by tourism, scenery, environment, weather, prices, or physical conditions, and individuals can acquire emotional experience and become inspired by events and the people around them).	e.g., “This morning, when I pulled back the curtain, a silver world appeared outside the window! Snow was everywhere, just lying on the trees. An unseasonable snowfall gave a surprise to spring. Particularly in these days of the hazy weather, the snow scene was a rare and beautiful thing.”

(c) Preference for spending time with family and close friends, rather than going to a party to obtain emotional satisfaction (sometimes, individuals need to feel needed and supported by others, and people acquire positive emotional experience by helping others).	e.g., “On the way to the library, a man asked me how to get to the classroom. I explained the way to him clearly and patiently. I had a strong feeling of presence and being needed as soon as he thanked me, which made me very happy.”

(d) A focus on the meaning of life and emotional intimacy (individual’s might seek to control their own moods or to engender a positive emotional experience).	e.g., “Although it was late, I still went for a walk with my friend. After I poured out my problems to her, I felt quite relaxed. She calmed me down and let me think about some things objectively. I thanked her a lot.”

(e) A focus on emotional rewards achieved through various activities or participation in social activities for the sake of an emotional experience.	e.g., “I had a good time with my friends at the beginning of this morning’s exercise. The teacher who taught us to make fans came to the classroom at 9:00. Some of her behaviors made us feel uncomfortable. I attended this class for pleasure, but I was unhappy. So I left the classroom and looked for pleasure elsewhere.”

(3) If an event could be classified as related to either an emotional or a knowledge-acquisition goal; it was classified as a mixed event.	e.g., “Today, in art class, the teacher taught us how to draw a peony. It was good to understand new things; it put us in a good mood and we gained something.”

(4) Descriptions of some events were too simple and did not contain distinguishing information. These events were considered non-specific.

Examples of these events include “Let the robot clean the house” or “Cooking meat for dinner.”


Method

MCODE

CFinder

CMC

RRW

COACH

CORE

Ours


Trait	Total cases	Pathologically confirmed cases

DLB	788	667

AD	959	113

PD	804	0


Pathway name	No. of genes	p-Value

Antigen processing and presentation	9	0

Chemokine signaling pathway	13	0

Complement and coagulation cascades	7	0

Cytokine-cytokine receptor interaction	23	0

Natural killer cell mediated cytotoxicity	9	0

Classical Complement Pathway	3	1.00E-04

Complement Pathway	3	4.00E-04

Alternative Complement Pathway	2	0.0021

Granzyme A mediated Apoptosis Pathway	2	0.0036

Toll-like receptor signaling pathway	4	0.0071

Intestinal immune network for IgA production	3	0.009

CCR3 signaling in Eosinophils	2	0.0111

Caspase Cascade in Apoptosis	2	0.0121

NOD-like receptor signaling pathway	3	0.0121

MAPK signaling pathway	6	0.0168

ECM-receptor interaction	3	0.0232

Jak-STAT signaling pathway	4	0.0284

IFN gamma signaling pathway	1	0.0478

B Lymphocyte Cell Surface Molecules	1	0.0611

T cell receptor signaling pathway	3	0.069

Pathway name

Antigen processing and presentation

Chemokine signaling pathway

Complement and coagulation cascades

Cytokine-cytokine receptor interaction

Natural killer cell mediated cytotoxicity

Classical Complement Pathway

Complement Pathway

Alternative Complement Pathway

Granzyme A mediated Apoptosis Pathway

Toll-like receptor signaling pathway

Intestinal immune network for IgA production

CCR3 signaling in Eosinophils

Caspase Cascade in Apoptosis

NOD-like receptor signaling pathway

MAPK signaling pathway

ECM-receptor interaction

Jak-STAT signaling pathway

IFN gamma signaling pathway

B Lymphocyte Cell Surface Molecules

T cell receptor signaling pathway


	n	%	Median	Range	Interquartile range

Wait time for first visit (time 1)			6	1–24	3–9

 1 month	3	5.3%

 2 months	7	12.3%

 3 months	10	17.5%

 4 months	4	7.0%

 5 months	1	1.8%

 6 months	10	17.5%

 7 months	2	3.5%

 8–9 months	5	8.8%

 10–12 months	7	12.3%

 13–18 months	5	8.8%

 19–24 months	3	5.3%

Wait time from first visit to diagnosis (time 2)			1	0–6.5	0.5–2

 0 months	7	12.3%

 0.25 months	3	5.3%

 0.5 months	5	8.8%

 0.75 months	5	8.8%

 1 month	18	31.6%

 1.5 months	2	3.5%

 2 months	7	12.3%

 3 months	4	7.0%

 4.5 months	2	3.5%

≥ 6 months	4	7.0%

Total wait from referral to diagnosis			7	2–26	4–12

< 2 months	3	5.3%

 2–3 months	6	10.5%

 4 months	6	10.5%

 5–6 months	7	12.3%

 7–8 months	9	15.8%

 9–10 months	8	14.0%

 11–12 months	2	3.5%

 13–14 months	6	10.5%

 15–18 months	3	5.3%

 19–22 months	4	7.0%

 23–26 months	3	5.3%

	n	%	Median	Range	Interquartile range

3 months	10	17.5%

4 months	4	7.0%

5 months	1	1.8%

6 months	10	17.5%

7 months	2	3.5%

8–9 months	5	8.8%

10–12 months	7	12.3%

13–18 months	5	8.8%

19–24 months	3	5.3%

Wait time from first visit to diagnosis (time 2)			1	0–6.5	0.5–2

0 months	7	12.3%

0.25 months	3	5.3%

0.5 months	5	8.8%

0.75 months	5	8.8%

1 month	18	31.6%

1.5 months	2	3.5%

2 months	7	12.3%

3 months	4	7.0%

4.5 months	2	3.5%

≥ 6 months	4	7.0%

Total wait from referral to diagnosis			7	2–26	4–12

< 2 months	3	5.3%

2–3 months	6	10.5%

4 months	6	10.5%

5–6 months	7	12.3%

7–8 months	9	15.8%

9–10 months	8	14.0%

11–12 months	2	3.5%

13–14 months	6	10.5%

15–18 months	3	5.3%

19–22 months	4	7.0%

23–26 months	3	5.3%


Predisposing factor	Mechanism of action

Moisture [1, 3, 12]	Increased relative moisture of the skinDamage to the skin barrier

Friction [3, 10, 11]	Friction between diaper and damp skin increases skin damage (convex regions)

Urine [1, 3, 9]	Presence of urea causes irritation and is the base product for conversion to ammonia

Feces [1, 3, 9, 13, 20]	The presence of lipases and proteases causes skin damage with filaggrin proteolysis and increased NMFa and TWELb

Ammonia and increased pH [1, 3, 12, 13]	Conversion of urea to ammonium hydroxide by bacterial flora (main responsible, Bacillus ammoniagenes)Increase in pH from 5.5 to 6.8–7.15

Microorganisms [1, 3, 12, 13, 16–19, 21, 22]	BacteriaStaphylococcus aureus (isolated most frequently)Other: (β-hemolytic) Streptococcus sp., E. coli and Bacteroides sp.More than 80 %C. albicans (80−90 %)Other: C. tropicalis, C. parapsilosis, C. glabrata

Use of antibiotics [1, 3, 9, 21, 22]	Use of broad-spectrum antibiotics causes increased Candida spp.

Association with other conditions [1, 3, 11]	Seborrheic dermatitis, inverse psoriasis, epidermolysis bullosa, granuloma gluteale infantum and acrodermatitis enteropathica

Predisposing factor

Moisture [1, 3, 12]

Friction [3, 10, 11]

Urine [1, 3, 9]

Feces [1, 3, 9, 13, 20]

Ammonia and increased pH [1, 3, 12, 13]

Microorganisms [1, 3, 12, 13, 16–19, 21, 22]

Use of antibiotics [1, 3, 9, 21, 22]

Association with other conditions [1, 3, 11]

Mechanism of action

Increased relative moisture of the skinDamage to the skin barrier

Friction between diaper and damp skin increases skin damage (convex regions)

Presence of urea causes irritation and is the base product for conversion to ammonia

The presence of lipases and proteases causes skin damage with filaggrin proteolysis and increased NMFa and TWELb

Conversion of urea to ammonium hydroxide by bacterial flora (main responsible, Bacillus ammoniagenes)Increase in pH from 5.5 to 6.8–7.15

BacteriaStaphylococcus aureus (isolated most frequently)Other: (β-hemolytic) Streptococcus sp., E. coli and Bacteroides sp.More than 80 %C. albicans (80−90 %)Other: C. tropicalis, C. parapsilosis, C. glabrata

Use of broad-spectrum antibiotics causes increased Candida spp.

Seborrheic dermatitis, inverse psoriasis, epidermolysis bullosa, granuloma gluteale infantum and acrodermatitis enteropathica


Plastid type	Plastid size (μm)	Protein content (pg/plastid)

Chloroplasts (7-days-old light-grown leaves)	3.24 ± 0.23	8.13 ± 1.42

Leucoplasts (4-days-old dark-grown roots)	1.81 ± 0.21	1.85 ± 0.63

Plastid type	Plastid size (μm)

Chloroplasts (7-days-old light-grown leaves)	3.24 ± 0.23

Leucoplasts (4-days-old dark-grown roots)	1.81 ± 0.21

Protein content (pg/plastid)

8.13 ± 1.42

1.85 ± 0.63


Variable		Change in Mean CSA	Change in Type II CSA	Change in Type I CSA


Formula	Observations	Grade

F1	Rapidly forming clear emulsion	A

F2	Rapidly forming clear emulsion	A

F3	Rapidly forming clear emulsion	A

F4	Rapidly forming clear emulsion	A

F5	Rapidly forming clear emulsion	A

F6	Rapidly forming clear emulsion	A

F7	Rapidly forming clear emulsion	A

F8	Rapidly forming clear emulsion	A


Primary antibody	Manufacturer (Cat. No.)	Pretreatment	Working dilution

Mouse anti-CD20 monoclonal antibody	Zymed, San Diego, CA, USA (18-0155)	HP CB (pH 6.0)	1:100

Mouse anti-CD79A monoclonal antibody	Novocastra, New Castle, Tyne and Wear, UK (RTU-CD79α-192)	HP CB (pH 6.0)	Ready to use

Mouse anti-CD3ε monoclonal antibody	Novocastra, New Castle, Tyne and Wear, UK (RTU-CD3-PS1)	HP CB (pH 6.0)	Ready to use

Mouse anti-CD45RO monoclonal antibody	Zymed, San Diego, CA, USA (08-1365)	HP CB (pH 6.0)	Ready to use

Mouse anti-CD5 monoclonal antibody	Zymed, San Diego, CA, USA (08-1283)	HP CB (pH 6.0)	Ready to use

Mouse anti-CD10 monoclonal antibody	Novocastra, New Castle, Tyne and Wear, UK (RTU-CD10-270)	HP CB (pH 6.0)	Ready to use

Mouse anti-CD23 monoclonal antibody	Novocastra, New Castle, Tyne and Wear, UK (RTU-CD23-1B12)	HP CB (pH 6.0)	Ready to use

Mouse anti-CD30 monoclonal antibody	Zymed, San Diego, CA, USA (08-0155)	HP CB (pH 6.0)	Ready to use

Mouse anti-CD56 monoclonal antibody	Zymed, San Diego, CA, USA (08-0152)	HP CB (pH 6.0)	Ready to use

Mouse anti-Bcl-6 monoclonal antibody	Zymed, San Diego, CA, USA (08-1426)	HP EDTA (pH 9.0)	Ready to use

Mouse anti-ALK monoclonal antibody	Zeta, Sierra Madre, CA, USA (Z2035)	HP EDTA (pH 8.0)	Ready to use

Mouse anti-Ki-67 monoclonal antibody	Zymed, San Diego, CA, USA (18-0192Z)	HP CB (pH 6.0)	1:50

Mouse anti-TdT monoclonal antibody	Zymed, San Diego, CA, USA (18-7237)	HP EDTA (pH 9.0)	1:50

Mouse anti-TIA-1 monoclonal antibody	Zeta, Sierra Madre, CA, USA (Z2183)	HP CB (pH 6.0)	Ready to use

Mouse anti-Perforin monoclonal antibody	Zeta, Sierra Madre, CA, USA (Z2118)	HP CB (pH 6.0)	Ready to use

Mouse anti-Granzyme B monoclonal antibody	Newmarket Scientific, Newmarket, Suffolk, UK (MS-1157-s)	HP CB (pH 6.0)	Ready to use

Mouse anti-PD-1 monoclonal antibody	Zymed, San Diego, CA, USA (0381)	HP CB (pH 6.0)	1:100

Goat anti-CXCL13 polyclonal antibody	Zymed, San Diego, CA, USA (0043)	HP CB (pH 6.0)	1:100

Mouse anti-CD4 monoclonal antibody	Zymed, San Diego, CA, USA (0032)	HP CB (pH 6.0)	1:200

Rabbit anti-CD8 monoclonal antibody	Zymed, San Diego, CA, USA (0043)	HP CB (pH 6.0)	1:100

Primary antibody	Manufacturer (Cat. No.)	Pretreatment	Working dilution

Mouse anti-Ki-67 monoclonal antibody	Zymed, San Diego, CA, USA (18-0192Z)	HP CB (pH 6.0)	1:50

Mouse anti-TdT monoclonal antibody	Zymed, San Diego, CA, USA (18-7237)	HP EDTA (pH 9.0)	1:50

Mouse anti-TIA-1 monoclonal antibody	Zeta, Sierra Madre, CA, USA (Z2183)	HP CB (pH 6.0)	Ready to use

Mouse anti-Perforin monoclonal antibody	Zeta, Sierra Madre, CA, USA (Z2118)	HP CB (pH 6.0)	Ready to use

Mouse anti-Granzyme B monoclonal antibody	Newmarket Scientific, Newmarket, Suffolk, UK (MS-1157-s)	HP CB (pH 6.0)	Ready to use

Mouse anti-PD-1 monoclonal antibody	Zymed, San Diego, CA, USA (0381)	HP CB (pH 6.0)	1:100

Goat anti-CXCL13 polyclonal antibody	Zymed, San Diego, CA, USA (0043)	HP CB (pH 6.0)	1:100

Mouse anti-CD4 monoclonal antibody	Zymed, San Diego, CA, USA (0032)	HP CB (pH 6.0)	1:200

Rabbit anti-CD8 monoclonal antibody	Zymed, San Diego, CA, USA (0043)	HP CB (pH 6.0)	1:100


 	Non-PD	PDa

Gender	Male	Female	Male	Female

Number	10	11	14 	12

Age (years)	70 ± 3.2 	71 ± 3.2	73 ± 2.1	73 ± 2.6

Disease duration (years)	NAb	NA	5.8 ± 0.60	4.8 ± 0.60


The nursing home as my home	Interpersonal care quality

‘Being at home in a nursing home’	‘Care for and alleviation of medical, physical and psychological needs’

‘Paying the price for 24-hour care’	‘Protecting the resident’s integrity’

‘Personal habits and institutional routines’	‘Psychosocial well-being’

‘Meaningful activities for a meaningful day’

The nursing home as my home

‘Being at home in a nursing home’

‘Paying the price for 24-hour care’

‘Personal habits and institutional routines’

‘Meaningful activities for a meaningful day’

Interpersonal care quality

‘Care for and alleviation of medical, physical and psychological needs’

‘Protecting the resident’s integrity’

‘Psychosocial well-being’


District name	Upazila Health Complex (UHC)	Samples (N)	K13 Nested PCR and sequencing N (%)	Non-synonymous Mutation N (%)

Bandarban	Lama UHC	14	149(100)	0(0.0)

Cox’s Bazar	Ramu and Ukhia UHC	74	69(93.2)	0(0.0)

Netrokona	Durgapur and Kalmakanda UHC	10	9(90)	0(0.0)

Mymensingh	Haluaghat UHC	2	2(100)	0(0.0)

Khagrachari	Matiranga UHC	154	144(93.5)	2*(1.29)

Rangamati	Rajasthali UHC	6	5(66.7)	0(0.0)

Moulvibazar	Sreemangal and Kamalganj UHC	11	11(100)	0(0.0)

	Total	271	254(93.7)	2(0.78)

District name	Upazila Health Complex (UHC)	Samples (N)	K13 Nested PCR and sequencing N (%)	Non-synonymous Mutation N (%)

Netrokona	Durgapur and Kalmakanda UHC	10	9(90)	0(0.0)

Mymensingh	Haluaghat UHC	2	2(100)	0(0.0)

Khagrachari	Matiranga UHC	154	144(93.5)	2*(1.29)

Rangamati	Rajasthali UHC	6	5(66.7)	0(0.0)

Moulvibazar	Sreemangal and Kamalganj UHC	11	11(100)	0(0.0)

	Total	271	254(93.7)	2(0.78)


Genomic resources	Source material	Number

Mapping populations

 DH line	Chiffu-401-42 × Kenshin-402-43	78 lines (F2 generation)

 RI line	Chiffu-401-42 × Kenshin-402-43	201 lines (F8 generation)

BAC libraries

 HindIII (KBrH) 	Chiffu-401-42	56592 clones (115 kb(1))

 BamHI (KBrB)	Chiffu-401-42	50688 clones (124 kb(1))

 Sau3AI (KBrS)	Chiffu-401-42	55296 clones (100 kb(1))

cDNA libraries

 22 cDNA libraries	Different tissues of Chiffu-401-42 and Jangwon including leaves, roots, cotyledons, stems,seedlings, ovules, siliques, anthers 	—

BAC-end sequences	KBrH, KBrB, and KBrS clones 	200017 sequences

ESTs	22 cDNA clones 	129928 sequences

BAC shotgun sequences	KBrH, KBrB, and KBrS clones	on-going(2)

Genomic resources	Source material	Number

BAC shotgun sequences	KBrH, KBrB, and KBrS clones	on-going(2)


Equipment contents of the emergency caesarean section tray	Equipment for neonatal resuscitation and stabilization

Scalpel with no. 10 blade	Overbed warmer

Lower end of Balfour retractor	Neonatal airway supplies

Pack of sponges	Umbilical access

2 Kelly clamps	Medications (e.g., epinephrine 1 : 10 000)

Needle driver

Russian forceps

Sutures and suture scissors

Equipment contents of the emergency caesarean section tray

Scalpel with no. 10 blade

Lower end of Balfour retractor

Pack of sponges

2 Kelly clamps

Needle driver

Russian forceps

Sutures and suture scissors

Equipment for neonatal resuscitation and stabilization

Overbed warmer

Neonatal airway supplies

Umbilical access

Medications (e.g., epinephrine 1 : 10 000)


Dataset	Proposed method

	(α=0.5)

USA - Netherlands	25.10%

USA - Belgium	19.04%

USA - Sweden	19.71%

Netherlands - Belgium	18.11%

Netherlands - Sweden	18.85%

Belgium - Sweden	17.13%


Admitting medical diagnosis 	Number of subjects (total n = 126)

Stroke (all types)	38

General medical (nonbrain)1	23

Brain tumor (all types)	22

Neurological disease (brain)2	20

Orthopedic3	14

Hydrocephalus (all types)	 9

Admitting medical diagnosis	Number of subjects (total n = 126)

Neurological disease (brain)2	20

Orthopedic3	14

Hydrocephalus (all types)	9


	Female	Male

Succeeded in returning to workplace **	49 (48.0 %)	237 (67.3 %)

Relapse of psychiatric symptoms **	37 (36.3 %)	71 (20.2 %)

Moved to another medical facility	6 (5.9 %)	12 (3.4 %)

Retirement or other	10 (9.8 %)	32 (9.1 %)

Total	102	352

	Female	Male

Relapse of psychiatric symptoms **	37 (36.3 %)	71 (20.2 %)

Moved to another medical facility	6 (5.9 %)	12 (3.4 %)

Retirement or other	10 (9.8 %)	32 (9.1 %)

Total	102	352


Variables	Correlation	P

FIQ	−0.32	<0.001

PCS	−0.55	< 0.001

HADS-dep	−0.57	<0.001

HADS-ans	−0.51	<0.001

Variables	Correlation	P

PVAS	−0.12	0.113

CPAQ	0.44	<0.001

MAS	0.39	<0.001


Gene category	List hits	Population hits	EASE score

(GO biological process)	(Total = 348)	(Total = 10,937)

response to external stimulus	67	1263	2.52E-05

 response to biotic stimulus	61	821	6.47E-10

 defense response	57	756	1.62E-09

 immune response	56	682	9.89E-11

 response to pest/pathogen/parasite	27	444	1.92E-03

 antigen processing, endogenous antigen via MHC class I	4	12	5.63E-03

response to stress	37	784	1.57E-02

signal transduction	97	2196	3.43E-04

 intracellular signaling cascade	47	761	1.62E-05

 protein kinase cascade	12	155	1.04E-02

 activation of MAPK	4	16	1.30E-02

phosphate metabolism	33	662	1.13E-02

 phosphorylation	28	524	8.90E-03

 protein amino acid phosphorylation	26	478	9.74E-03

RNA splicing, via transesterification reactions	8	83	1.61E-02

Gene category	List hits	Population hits	EASE score

(GO biological process)	(Total = 348)	(Total = 10,937)

RNA splicing, via transesterification reactions	8	83	1.61E-02


Exogenous variable	Endogenous variable

Arm movement speed (plate tapping)	Agility (10x5m shuttle run)	Explosive strength of the legs (standing broad jump)	Trunk strength (sit-ups)	Explosive strength of trunk and shoulder girdle (1kg medicine ball throw)	MAP	Flexibility (sit and reach)

Body height	−0.677	−0.635	0.638	0.581	0.702	0.309

Body mass		0.302

BMI					0.488		0.233

Rohrer’s index

∑ of skinfold thickness	0.123		−0.437	−0.220	−0.588		−0.455

LBM						0.605

Objective quality of life index		−0.177	0.216			0.114

Subjective quality of life index	0.110			−0.090			0.136

R	0.649	0.494	0.685	0.543	0.727	0.924	0.308

R2	0.422	0.244	0.469	0.295	0.529	0.854	0.095

F	22.620	9.992	27.370	13.002	34.862	181.37	3.255

p	0.000	0.000	0.000	0.000	0.000	0.000	0.025


Mikołajskie september	Mamry september

Microscope	DGGE-ITS	Microscope	DGGE-ITS

taxon	(cells/mL)	taxon	(cells/mL)

Snowella litoralis	3	 	Snowella litoralis	118

Snowella lacustris	31	 	Snowella lacustris	1

 	 	 	Woronichinia compacta	1

 	 	 	Woronichinia naegeliana	2

Chroococcus spp.	<1	 	Chroococcus spp.	13

 	 	 	Aphanothece spp.	779

 	 	 	Microcystis aeruginosa	19	Microcystis

 	 	 	Microcystis flos-aquae	7

 	 	 	Microcystis smithii	5

Aphanocapsa spp.	34	 	Aphanocapsa spp.	4599

Aphanocapsa planctonica	4	 	Aphanocapsa planctonica	75

 	 	 	Coelosphaerium kuetzingianum	2

Coelosphaerium minutissimum	3	 	Coelosphaerium minutissimum	18

 	 	 	Merismopedia punctata	1

Cyanodictyon reticulatum	2

 	 	 	Cyanodictyon cf. planctonicum	7

 	 	 	Lemmermanniella pallida	4

Synechococcus-like/Cyanobium-like	60042	Synechococcus	Synechococcus-like/Cyanobium-like	76386	Synechococcus

Aphanizomenon gracile	839	Aphanizomenon (?)	Aphanizomenon gracile	336	Aphanizomenon (?)

Cuspidothrix issatschenkoi	20	Cuspidothrix issatschenkoi	Cuspidothrix issatschenkoi	25	Cuspidothrix issatschenkoi

 	 	Dolichospermum	Dolichospermum lemmermannii	1	Dolichospermum

 	 	Phormidium (?)	 	 	Phormidium (?)

Planktothrix agardhii	45	Planktothrix	 	 	Planktothrix

Planktothrix suspensa

 	 	Pseudanabaenaceae	 	 	Pseudanabaenaceae

 	 	 	 	 	Leptolyngbya

Limnothrix lauterbornii	128	 	Limnothrix lauterbornii	154

Limnothrix redekei	692	 	Limnothrix redekei	742

Planktolyngbya limnetica	5455	 	Planktolyngbya limnetica	3293

Pseudanabaena catenata	5963	 	Pseudanabaena catenata	1393

Pseudanabaena limnetica	18172	 	Pseudanabaena limnetica	24635

 	 	 	Pseudanabaena mucicola	10

 	 	Romeria (?)	Romeria gracilis	214	Romeria (?)

 	 	unassigned sequences	 	 	unassigned sequences

 	 	nonsequenced	 	 	nonsequenced

Mikołajskie september	Mamry september

Microscope	DGGE-ITS	Microscope	DGGE-ITS

taxon	(cells/mL)	taxon	(cells/mL)

Snowella litoralis	3		Snowella litoralis	118

Snowel	3		Snowe	1

Mikołajskie september	Mamry september

Microscope	DGGE-ITS	Microscope	DGGE-ITS

taxon	(cells/mL)	taxon	(cells/mL)

la lacustris	1		lla lacustris

			Woronichinia compacta	1

			Woronichinia naegeliana	2

Chroococcus spp.	<1		Chroococcus spp.	13

			Aphanothece spp.	779

			Microcystis aeruginosa	19	Microcystis

			Microcystis flos-aquae	7

			Microcystis smithii	5

Aphanocapsa spp.	34		Aphanocapsa spp.	4599

Aphanocapsa planctonica	4		Aphanocapsa planctonica	75

			Coelosphaerium kuetzingianum	2

Coelosphaerium minutissimum	3		Coelosphaerium minutissimum	18

			Merismopedia punctata	1

Cyanodictyon reticulatum	2

			Cyanodictyon cf. planctonicum	7

			Lemmermanniella pallida	4

Synechococcus-like/Cyanobium-like	60042	Synechococcus	Synechococcus-like/Cyanobium-like	76386	Synechococcus

Aphanizomenon gracile	839	Aphanizomenon (?)	Aphanizomenon gracile	336	Aphanizomenon (?)

Cuspidothrix issatschenkoi	20	Cuspidothrix issatschenkoi	Cuspidothrix issatschenkoi	25	Cuspidothrix issatschenkoi

		Dolichospermum	Dolichospermum lemmermannii	1	Dolichospermum

		Phormidium (?)			Phormidium (?)

Planktothrix agardhii	45	Planktothrix			Planktothrix

Planktothrix suspensa

		Pseudanabaenaceae			Pseudanabaenaceae

					Leptolyngbya

Limnothrix lauterbornii	128		Limnothrix lauterbornii	154

Limnothrix redekei	692		Limnothrix redekei	742

Planktolyngbya limnetica	5455		Planktolyngbya limnetica	3293

Pseudanabaena catenata	5963		Pseudanabaena catenata	1393

Pseudanabaena limnetica	18172		Pseudanabaena limnetica	24635

			Pseudanabaena mucicola	10

		Romeria (?)	Romeria gracilis	214	Romeria (?)

		unassigned sequences			unassigned sequences

		nonsequenced			nonsequenced


Variable	Cases (n = 50)	Controls (n = 44)	p-values


 Causes of preterm labor	Spontaneous preterm labor	PROM	Preterm elective termination of pregnancy	Term labor

Group

Case (progesterone)

	Number	0	4	0	48

	Percentage	0%	7.7%	0%	92.3%

Control (placebo)

	Number	3	2	3	39

	Percentage	6.4%	4.3%	6.4%	83%


Characteristics	n = 60(%)	miR-335-5p mRNA expression	p value	CPNE1 mRNA expression	p value

high	low	high	low

(n = 15)	(n = 45)	(n = 53)	(n = 7)

Age

≤65	41 (68%)	9	32	0.432	36	5	0.851

> 65	19 (32%)	6	13	17	2

Gender

Male	38 (63%)	10	28	0.757	34	4	0.718

Female	22 (37%)	5	17	19	3

Histology

Adenocarcinoma	33 (55%)	7	26	0.479	30	3	0.661

Squamous cell carcinoma	17 (28%)	4	13	14	3


Dataset	Number	Overlap	P Valuea	Odds Ratio

Expressed genes for Smaug-dependent decay (embryos 2–3 hr)	3956

Smaug-dependent decay genes (embryos 2–3 hr, 5% FDR)b	418

Smaug-dependent-miR target genes	1507	151	4.9 × 10−6	1.6

Expressed genes for Smaug-dependent decay (embryos 2–3 hr)	3956

Smaug-dependent decay genes (embryos 2–3 hr, 5% FDR)c	341

Smaug-dependent-miR target genes	1507	128	3.1 × 10−6	1.7

Expressed genes for Smaug-RIP (embryos 0–3 hr)	4481

Smaug-RIP genes (embryos 0–3 hr, 5% FDR)	339

Smaug-dependent-miR target genes	1200	101	0.11	1.1

Dataset	Number	Overlap	P Valuea	Odds Ratio

Smaug-dependent decay genes (embryos 2–3 hr, 5% FDR)c	341

Smaug-dependent-miR target genes	1507	128	3.1 × 10−6	1.7

Expressed genes for Smaug-RIP (embryos 0–3 hr)	4481

Smaug-RIP genes (embryos 0–3 hr, 5% FDR)	339

Smaug-dependent-miR target genes	1200	101	0.11	1.1


Suspected VOC	Healthy vs. Benign + Cancer	Healthy + Benign vs. Cancer	Cancer vs. DCIS	Triple Negative vs. Other	HER2+ vs. Other	HER2 + status*vs. Other	HER2+ status (Non Luminal) vs. Other	HER2+ status (Luminal) vs. Other

Ethanol	X	X	X			X

Acetone					X		X

Cyclopentane				X

Carbonic acid, dimethyl ester (DMC)					X	X		X

Pentane, 2, 3-dimethyl-			X				X

Heptane		X	X

Toluene						X

Cyclohexane, 1, 4-dimethyl-				X				X

Acetic acid, butyl ester				X

Benzene, 1, 3-dimethyl-					X	X

2-Propenoic acid, butyl ester	X	X

alpha.-Pinene	X				X

5-Hepten-2-one, 6-methyl-		X

1-Hexanol, 2-ethyl-			X

Sensitivity	86	78	70	40	67	68	100	73

Specificity	70	61	83	95	76	72	57	70

Accuracy	83	72	81	87	74	70	82	72

p-value	< 0.0001	< 0.0001	0.0001	0.006	0.0001	< 0.0001	0.0047	0.0018

AUC	0.93	0.79	0.88	0.78	0.83	0.82	0.91	0.87

Suspected VOC	Healthy vs. Benign + Cancer	Healthy + Benign vs. Cancer	Cancer vs. DCIS	Triple Negative vs. Other	HER2+ vs. Other	HER2 + status*vs. Other	HER2+ status (Non Luminal) vs. Other	HER2+ status (Luminal) vs. Other

Ethanol	X	X	X			X

Acetone					X		X

Cyclopentane				X

Carbonic acid, dimethyl ester (DMC)					X	X		X

Pentane, 2, 3-dimethyl-			X				X

Heptane		X	X

Toluene						X

Cyclohexane, 1, 4-dimethyl-				X				X

Acetic acid, butyl ester				X

Benzene, 1, 3-dimethyl-					X	X

2-Propenoic acid		X


Clinical manifestations/Hospitalization	Number of events	Number of doses per event	Rate per 10,000 dosesb

Local

	Pain	189	4,040	2.5

	Nodule	163	4,684	2.1

	Abscess	33	23,138	0.4

	Lymphadenitis	33	23,138	0.4

	Ulcer	1	763,548	0.1

Systemic

	Headache	1	763,548	0.1

	Nausea	10	76,355	0.1

	Diarrhea	23	33,198	0.3

	Vomiting	54	14,140	0.7

	Cyanosis	27	28,280	0.4

	Malaise	23	33,198	0.3

	Irritability	102	7,486	1.3

	Sleepiness	44	17,353	0.6

	Myalgia	7	109,078	0.1

	Exanthema	46	16,599	0.6

	Jaundice	1	763,548	0.1

	Parotitis	20	38,177	0.3

	Fever	344	2,220	4.5

	< 38°C	51	14,971	0.7

	38|-|39,4°C	196	3,896	2,6

	≥ 39.5°C	68	11,229	0.9

	Hypotonic-hyporesponsive episode	67	11,396	0.9

	Adenoiditis	18	42,419	0.2

	Arthralgia	1	763,548	0.1

	Hypersensitivity	11	69,413	0.1

	Seizure	25	30,542	0.3

	Loss of consciousness	6	127,258	0.1

	Myelitis	1	763,548	0.1

	Paresis	1	763,548	0.1

Hospitalization	16	47,722	0.2

Clinical manifestations/Hospitalization

Local

Systemic

Hospitalization


Criterion	ALARM (n,%)	Control (n,%)	p-value

	N = 68	N = 70

Albumin test

Yes	18, 26.5%	18, 26.1%

No	50, 73.5%	51, 73.9%	1.00

Total severe (pre-) eclampsia score	25.2%	23.2%	0.621


		Strain	NRRL2338	Px

COG	Functional categories	% COG probesets	% Probesets with q-value < = 0.001	% Probesets with q-value < = 0.001

I	Cellular processes and signaling

I.1	Cell cycle control, cell division, chromosome partitioning	0,35	0,99	0,69

I.2	Cell motility	0,01	0	0

I.3	Cell wall/membrane/envelope biogenesis	2,05	3,22	3,81

I.4	Defense mechanisms	0,89	0,00	0,87

I.5	Intracellular trafficking, secretion, and vesicular transport	0,24	0,25	0,69

I.6	Posttranslational modification, protein turnover, chaperones	1,90	5,94	3,99

I.7	Signal transduction mechanisms	1,91	0,99	1,91

II	Information storage and processing

II.1	Amino acid transport and metabolism	0,01	0	0

II.2	Cell wall/membrane/envelope biogenesis	0,01	0	0

II.3	Chromatin structure and dynamics	0,01	0	0

II.4	General function prediction only	0,30	0,50	0,35

II.5	Nucleotide transport and metabolism	0,07	0	0

II.6	Posttranslational modification, protein turnover, chaperone	0,04	0	0

II.7	Replication, recombination and repair	2,44	0,74	2,43

II.8	RNA processing and modification	0,01	0

II.9	Secondary metabolites biosynthesis, transport catabolism	0,04	0

II.10	Signal transduction mechanisms	0,71	0,50	0,69

II.11	Transcription	7,20	2,23	3,29

II.12	Translation, ribosomal structure and biogenesis	2,48	4,21	10,75

III	Metabolism

III.l	Amino acid transport and metabolism	6,60	0	8,15

III.2	Carbohydrate transport and metabolism	6,08	7,67	6,59

III.3	Cell wall/membrane/envelope biogenesis	0,38	0	0,17

III.4	Coenzyme transport and metabolism	2,63	5,20	4,33

III.5	Energy production and conversion	4,79	9,90	8,15

III.6	Inorganic ion transport and metabolism	2,68	4,21	2,25

III.7	Lipid transport and metabolism	4,24	2,72	5,03

III.8	Nucleotide transport and metabolism	1,27	2,97	3,64

III.9	Posttranslational modification, protein turnover, chaperones	0,08	0	0,17

III.10	Secondary metabolites biosynthesis, transport catabolism	2,90	2,48	2,77

III. 11	Signal transduction mechanisms	0,16	0	0

IV	Poorly characterized

IV.1	Function unknown	32,11	27,23	22,70

IV.2	General function prediction only	7,37	8,17	6,59

	Total probesets	7060	404	577


No.	Name	Concentration of β-asarone (mg/kg)	Concentration of α-asarone (mg/kg)	Source

1	Product 1	Not detected	Not detected	–

2	Product 2	Not detected	Not detected	–

3	Product 3	273.6 ± 21.6	40 ± 1.2	Acori tatarinowii Rhizoma

4	Product 4	Not detected	Not detected	–

5	Product 5	230.9 ± 21.3	34.7 ± 1.2	Acori tatarinowii Rhizoma

6	Product 6	4.8 ± 0.2	5.0 ± 0.2	Acori tatarinowii Rhizoma

7	Product 7	11.2 ± 0.1	47.7 ± 3.0	Acori graminei Rhizoma

8	Product 8	181.6 ± 5.4	106.1 ± 1.0	–

9	Product 9	Not detected	Not detected	–

10	Product 10	Not detected	Not detected	–

11	Product 11	181.6 ± 5.4	106.1 ± 1.0	unknown source

12	Product 12	4.3 ± 0.3	13.3 ± 0.1	unknown source

13	Product 13	3.2 ± 0.2	10.9 ± 3.3	Asari radix et Rhizoma

14	Product 14	241.5 ± 10.5	53.2 ± 1.2	unknown source

15	Product 15	Not detected	Not detected	–

16	Product 16	Not detected	Not detected	–

17	Product 17	Not detected	Not detected	–

18	Product 18	243.5 ± 18.2	144.3 ± 7.1	unknown source

19	Product 19	Not detected	Not detected	–

20	Product 20	425.7 ± 28.2	62.8 ± 3.1	Acori tatarinowii Rhizoma

21	Authentic herb Acori tatarinowii	7679.8 ± 85.7	679.1 ± 20.3	Acori tatarinowii Rhizoma

No.	Name	Concentration of β-asarone (mg/kg)	Concentration of α-asarone (mg/kg)	Source

1	Product 1	Not detected	Not detected	–

2	Product 2	Not detected	Not detected	–

3	Product 3	273.6 ± 21.6	40 ± 1.2	Acori tatarinowii Rhizoma

4	Product 4	Not detected	Not detected	–

5	Product 5	230.9 ± 21.3	34.7 ± 1.2	Acori tatarinowii Rhizoma

6	Product 6	4.8 ± 0.2	5.0 ± 0.2	Acori tatarinowii Rhizoma

7	Product 7	11.2 ± 0.1	47.7 ± 3.0	Acori graminei Rhizoma

8	Product 8	181.6 ± 5.4	106.1 ± 1.0	–

9	Product 9	Not detected	Not detected	–

1	Product	Not 	Not detected

No.	Name	Concentration of β-asarone (mg/kg)	Concentration of α-asarone (mg/kg)	Source

0	 10	detected		–

11	Product 11	181.6 ± 5.4	106.1 ± 1.0	unknown source

12	Product 12	4.3 ± 0.3	13.3 ± 0.1	unknown source

13	Product 13	3.2 ± 0.2	10.9 ± 3.3	Asari radix et Rhizoma

14	Product 14	241.5 ± 10.5	53.2 ± 1.2	unknown source

15	Product 15	Not detected	Not detected	–

16	Product 16	Not detected	Not detected	–

17	Product 17	Not detected	Not detected	–

18	Product 18	243.5 ± 18.2	144.3 ± 7.1	unknown source

19	Product 19	Not detected	Not detected	–

20	Product 20	425.7 ± 28.2	62.8 ± 3.1	Acori tatarinowii Rhizoma

21	Authentic herb Acori tatarinowii	7679.8 ± 85.7	679.1 ± 20.3	Acori tatarinowii Rhizoma


Characteristic	Patients with asthma	Patients without asthma	P-Value*

 	No. (%) (n = 137)	No. (%) (n = 336)

Tachypnea	60/137 (44)	110/336 (33)	0.07

Tachycardia	88/137 (64)	213/336 (63)	0.86

Intensive care unit admission	37/133 (28)	108/321 (34)	0.31

Mechanical ventilation	16/127 (13)	69/301 (23)	0.02

Acute respiratory distress syndrome	9/129 (7)	38/292 (13)	0.10

Sepsis syndrome	7/128 (6)	31/291 (11)	0.12

Death	5/137 (4)	32/332 (10)	0.04

Influenza antiviral agent receipt

 Any during hospitalization	101/137 (74)	270/336 (80)	0.15

 ≤ 2 days of illness onset	49/99 (50)	106/269 (39)	0.10

 ≤ 2 days of admission	79/92 (86)	219/253 (87)	0.87

 Median days from illness onset to antiviral initiation (range)	3 (0 – 18)	3 (0 – 32)	0.06

Other treatment

 Antibiotics	101/137 (74)	260/336 (77)	0.40

 Steroids	83/137 (61)	96/336 (29)	<0.01

Characteristic	Patients with asthma

	No. (%) (n = 137)

Tachypnea	60/137 (44)

Tachycardia	88/137 (64)

Intensive care unit admission	37/133 (28)

Mechanical ventilation	16/127 (13)

Acute respiratory distress syndrome	9/129 (7)

Sepsis syndrome	7/128 (6)

Death	5/137 (4)

Influenza antiviral agent receipt

Any during hospitalization	101/137 (74)

≤ 2 days of illness onset	49/99 (50)

≤ 2 days of admission	79/92 (86)

Median days from illness onset to antiviral initiation (range)	3 (0 – 18)

Other treatment

Antibiotics	101/137 (74)

Steroids	83/137 (61)


Films with Agarose Mass Concentrations (%)	Areas of the Antibacterial Zone (A, mm2)

S. aureus

0	89.29 ± 1.23

20	78.89 ± 0.89

40	71.64 ± 2.06

60	70.56 ± 1.55

80	22.09 ± 1.17


Treatment priority	Probability

0	0.1

1	0.2

2	0.3

3	0.4


Item	PTV location

PTV CI	WV

PG

SS

BG

PTV GI	WV

PG

SS

BG

PTV HI	WV

PG

SS

BG

PTV PQI	WV

PG

SS

BG